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AMPHIPHILIC CYCLOBUTENES AND
CYLOBUTANES

wherein :

represents an optionally present double bond ;
sisting of: H , halo , ORS, and = 0 ;
CROSS -REFERENCE TO RELATED
5 R² is absent or is an optionally substituted C -C40 alkyl;
APPLICATIONS
R * is H or an optionally substituted C -C40 alkyl; and
This application is a National Stage Application under 35 Z is selected from the group consisting of: COR®, CO Rº,
NHC( O )NR R7, CONR , OCOR , OR , SR , NR R7
U.S.C. $ 371 and claims the benefit of International Appli

R ' and R are independently selected from the group con

and OPO , R ;

cation No. PCT/US2013 /042897 , filed on May 28 , 2013 ,

which claims priority to U.S. application Ser. Nos. 61/651, 10 Rºis H or C -Co alkyl;

R and R ’ are independently H or C -Co alkyl;
wherein the hydrocarbon backbone formed by R * and R3- Z
is amphiphilic ,
with the proviso that the compound of Formula (I) is not:

752 , filed on May 25 , 2012 , and 61/702,782 , filed on Sep.
19 , 2012 , both of the disclosures of which are incorporated
by reference in their entireties herein .
TECHNICAL FIELD

15

This disclosure relates to amphiphilic compounds con

taining a cyclobutene or cyclobutane moiety. In some
embodiments, the compounds are useful for treating infec

tion by mycobacterium such as Mycobacterium tuberculosis. 20
Cyclobutene containing compounds are also useful as mono

mers in the preparation of amphiphilic polymers.
BACKGROUND

Tuberculosis resulting from infection by Mycobacterium

25

tuberculosis (M.tb ) poses a significant disease threat. Based
on skin test reactivity , it is estimated that one - third of the
world's population has been exposed , resulting annually in
approximately nine million cases and 1.4 million deaths 30
(2010 data ) (see Raviglione, M. et al. Lancet 2012 , 379 ,
1902-1913 ). The current vaccine, M. bovis BCG , yields
inconsistent protection and can interfere with diagnostic skin
tests. Although numerous candidate vaccines are being
tested , their overall safety and efficacy has not been estab- 35
lished . Although a number of therapeutic agents have been
developed , current treatment regimens require patients to
take multiple drugs over a period ofmonths. This , combined
with significant drug side effects, commonly results in
patient noncompliance leading to relapses and the emer- 40
gence of drug resistance; 3 a high fraction of active cases

or

involve multi-drug resistant (MDR , XDR ) strains.
SUMMARY

45
In some embodiments , the compound provided herein can
It is believed that much of the hardiness and drug resis be
used in a method for treating a mycobacterial infection in
tance ofmycobacteria are due to an unusually thick lipid cell
, themethod comprising administering to the patient
wall containing a significant proportion ofmycolic acids, a aa patient
therapeutically
effective amount of a compound of For
unique class of C54 -C63 branched -chain fatty acids. A num mula (I) or a pharmaceutically
acceptable salt thereof. For
ber
of
existing
treatments
for
M.
tb
,
exemplified
by
isoniazid
50
example
,
a
compound
provided
can be used to treat
and ethionamide, inhibit mycolic acid biosynthesis. Myco a mycobacterial infection such asherein
M. tuberculosis .
bacteria incorporate C16 and C18 fatty acids as biosynthetic
Further provided herein are polymers prepared from a
feedstocks. The compounds provided herein mimic these compound
of Formula (IV ):
feedstocks and the uptake of these specifically functional
ized fatty acids is thought to inhibit downstream mycolic 55
acid biosynthesis, leading to virulence- attenuating or even
lethal alterations in the mycobacterial cell wall structure .
Provided herein are compounds of Formula (I):
R4
R3 - Z

R!

R2

60

or a pharmaceutically acceptable salt thereof,
wherein :

R3 is absent or is an optionally substituted C , -C40 alkyl;

R4

R3 — Z

or a pharmaceutically acceptable salt thereof,

R4 is H or an optionally substituted CZ- C40 alkyl; and
65 Z is selected from the group consisting of: CORE, CO ,Rº,
NHC (O )NRØR ?, CONR , OCOR , OR , SR , NRÖR ?,
and OPOZR®;

US 10,538,475 B2
3

4

R $ is H or C , -C6 alkyl;
Rand R7 are independently H or C.-C. alkyl;
wherein the hydrocarbon backbone formed by R4 and R3_Z
is amphiphilic.

FIG . 3 shows the minimum inhibitory concentrations
(MICS) of eleven analogs against M. smeg . (mc2155 ) and

M. tb (CDC1551 and H37Rv).
FIG . 4 illustrates the cytotoxicity of 1 measured in RAW

For example, a compound of Formula (IV ) can be pre- 5 264.7 cells .

pared by reacting an unsaturated fatty acid or derivative
thereof having a backbone comprising at least one carbon
carbon double bond with dihaloketene to achieve a stereo
specific cycloaddition across the at least one carbon -carbon

double bond , thereby yielding a cycloketone -containing
fatty acid derivative comprising a cycloketone along the

DETAILED DESCRIPTION

Definitions
10

For the terms “ for example” and “ such as,” and gram

equivalences thereof, the phrase " and without limi
backbone , wherein the cycloketone comprises at least four matical
tation
”
understood to follow unless explicitly stated
carbon atoms, with at least two of the at least four carbon otherwiseis. As
used herein , the term “ about” is meant to
atoms being part of the backbone of the cycloketone 15 account for variations
due to experimental error. All mea
containing fatty acid derivative; reducing the cycloketone surements reported herein
understood to be modified by
containing fatty acid derivative to yield an amphiphilic the term “ about” , whether are
or not the term is explicitly used ,
cycloalkene-containing fatty acid derivative having a hydro
unless explicitly stated otherwise. As used herein , the sin

phobic end , a hydrophilic end , and a backbone therebetween gular forms “ a,” “ an ,” and “ the” include plural referents
comprising a cycloalkene, wherein the cycloalkene com- 20 unless the context clearly dictates otherwise .
prises at least four carbon atoms, with at least two of the four
The term “ alkyl” includes straight- chain alkyl groups
carbon atomsbeing part of the backbone of the amphiphilic (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl , heptyl,
octyl, nonyl, decyl, etc.) and branched -chain alkyl groups
cycloalkene -containing fatty acid derivative .
In some embodiments, a multiplicity of compounds of (e.g., isopropyl, tert -butyl, isobutyl, etc.). In certain embodi
Formula ( IV ) can be polymerized to yield a polymer com- 25 ments , a straight chain or branched chain alkylhas twelve or

prising carbon -carbon double bonds. In some such embodi fewer carbon atoms in its backbone (e.g., C7-C12 for straight
ments , the polymerization can further include hydrogenating chain ; C3-C12 for branched chain ). The term C ,1 -C12 includes
the carbon -carbon double bonds of the polymer; cleaving at alkyl groups containing 1 to 12 carbon atoms.
least some of the carbon -carbon double bonds in the poly
The term “ alkenyl” includes aliphatic groups that may or
mer via oxidation to yield monomeric products; cross- 30 may not be substituted , as described above for alkyls,
linking the amphiphilic cycloalkene-containing fatty acid containing at least one double bond and at least two carbon
derivatives via the carbon - carbon double bond in the atoms. For example , the term “ alkenyl” includes straight
cycloalkene; ring -opening metathesis reactions; aligning the chain alkenyl groups (e.g., ethenyl, propenyl, butenyl, pen
backbones of the multiplicity of the amphiphilic cycloalk
tenyl, hexenyl, heptenyl, octenyl, nonenyl, and decenyl) and
ene
containing
fatty
acid
derivatives
before
polymerizing
35
branched
-chain alkenyl groups. In certain embodiments, a
the multiplicity of the amphiphilic cycloalkene - containing straight chain or branched chain alkenyl group has twelve or
fatty acid derivatives; polymerizing via click -chemistry; and fewer carbon atoms in its backbone (e.g., C2-C12 for straight
mixtures thereof.
chain ; C3 -C12 for branched chain ). The term C2- C12 includes
Unless otherwise defined , all technical and scientific alkenyl groups containing 2 to 12 carbon atoms.
terms used herein have the same meaning as commonly 40 The term " alkynyl” includes unsaturated aliphatic groups
understood by one of ordinary skill in the art to which this analogous in length and possible substitution to the alkyls
invention belongs. Methods and materials are described described above , but which contain at least one triple bond
herein for use in the present invention ; other, suitable and two carbon atoms. For example, the term “ alkynyl”
methods and materials known in the art can also be used . includes straight- chain alkynyl groups (e.g., ethynyl, pro
The materials, methods, and examples are illustrative only 45 pynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nony
and not intended to be limiting . All publications, patent nyl, and decynyl) and branched -chain alkynyl groups. In
applications, patents, sequences, database entries , and other certain embodiments, a straight chain or branched chain
references mentioned herein are incorporated by reference in alkynyl group has twelve or fewer carbon atoms in its
their entirety. In case of conflict, the present specification , backbone (e.g., C2-C12 for straight chain ; Cz-C12 for
50 branched chain ). The term C2 -C12 includes alkynyl groups
including definitions, will control.
Other features and advantages of the invention will be containing 2 to 12 carbon atoms.
apparent from the following detailed description and figures ,
The term “ alkoxy ” is used in its conventional sense, and
and from the claims.
refers to alkyl groups linked to molecules via an oxygen
atom . In some embodiments , an alkoxy has twelve or fewer
DESCRIPTION OF DRAWINGS
55 carbon atoms in its backbone (e.g. , a C , -C12 alkoxy). For
example, C -C10 , C.-Cg, C.-C., C. -C4, C.- Cz, or C.-C.
FIG . 1 illustrates the thermal stability of cyclobutene 1. y Non - limiting examples of an alkoxy group include methoxy,
axis is weight in mg for the lower line and heat flow endo ethoxy , propoxy , butoxy , and hexoxy .
down in mW for top line .
The terms “ halo ” or “ halogen ” , used alone or in combi
FIG . 2 shows 1D ' H NMR spectra of compounds (A ) 1 60 nation with other terms, refers to fluoro , chloro , bromo and
and (B ) 8 that were inspected for evidence of micelle iodo .
formation (peak broadening ) by comparing peak widths
The term “haloalkyl” refers to an alkyl group in which one
relative to TMSP (standard ). Peak widths for compound 1 or more of the hydrogen atoms has been replaced by a
exhibited potential micelle formation or aggregation over halogen atom . The term “ Cn Cm haloalkyl” refers to a
the range of tested concentrations (highlighted region ). No 65 Cm Cm alkyl group having n to m carbon atoms, and from
micelle formation was observed for compound 8 over the at least one up to {2 (n to m ) +1 } halogen atoms, which may
concentrations of 100 uM , 500 uM , 750 uM , and 1000 uM . either be the same or different. In some embodiments , the

US 10,538,475 B2
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halogen atoms are fluoro atoms. In some embodiments , the NO2, ORCI, SRal, C (ORI, C (O )NR TROI, C (O )Oral ,
haloalkyl group has 1 to 6 or 1 to 4 carbon atoms. Example OCTORb1, OC (O )NRCIRDI, CENREI NRCIRI, NRC
haloalkyl groups include CF3, C2F5, CHF2, CC13, CHC12, ( NREI)NRCIRI, NRCIRII, NRCIC (O )RbI, NRCIC (O )
C2Cl
, and the like . In some embodiments , the haloalkyl Oral, NRC C (O )NRCRd1, NRCIS(O )RBI, NRC'S (O ),Rb1,
group is a fluoroalkyl group .
(O )2NRCIRII, S (O )R51, S (O )NRCIRI, S (O ),Rb1 and
The term “ haloalkoxy ” , employed alone or in combina 5 NRCS
S
(
O
)
NRORI
tion with other terms, refers to a group of formula 0
each Cyl is independently C6-10 aryl, C3.10 carbocyclyl,
haloalkyl, wherein the haloalkyl group is as defined above. 5-10 membered heteroaryl or 4-10 membered heterocyclyl,
The term “ CnCm haloalkoxy ” refers to a haloalkoxy
of which is unsubstituted or substituted by 1, 2 , 3 , 4 or
group , the haloalkyl group of which has n to m carbons. 10 each
5 substituents independently selected from C1-6 alkyl, C2-6
Example haloalkoxy groups include trifluoromethoxy and alkenyl
, C2-6 alkynyl, halo , CN ,NO , ORI, SRI, C (ORI
the like . In some embodiments , the haloalkoxy group has 1 CONRCIRd
, C (O )ORT, OCOR , OC(O )NRC?Rd ,
to 6 , 1 to 4 , or 1 to 3 carbon atoms.
CENRI) NRCIRI NRCCNR )NRCIRI NR RI,
The term “ amino ” refers to a group of formula -NH2. NR
- C (O )R51,NRCIC (O )ORI, NRCIC (O )NRCRAI, NR IS
The term “ carbamyl” refers to a group of formula - C (O ) 15 (O )RI
,NRCIS (O ), R01,NRCS(O )2NRCIRd!, (O )RbI, S (O )
NH2

, S,(Rbi
O ),,RbíRei,,sR1
(0 ), NRCIRái
and oxoselected
; from H ,
The term “ carbonyl” , employed alone or in combination NRCIRI
Ral
is independently
with other terms, refers to a CEO) — group , which also C1-6eachalkyl
, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10
may be written as C (O ).
aryl, C3-10 carbocyclyl, 5-10 membered heteroaryl, 4-10
The term “ oxo ” refers to oxygen as a divalent substituent, 20 membered
heterocyclyl, C6-10 aryl-C -4 alkyl, C3-10 carbo
forming a carbonyl group, or attached to a heteroatom
-C1-4 alkyl , (5-10 membered heteroaryl)-C1-4 alkyl or
forming a sulfoxide or sulfone group, or an N -oxide group . cyclyl
(4-10 membered heterocyclyl) -C -4 alkyl, wherein said C1-6
The term " aromatic ” refers to a carbocycle or heterocycle alkyl
, C., alkenyl , C2. alkynyl, C6-10 aryl, C3.10 carbocy
having one or more polyunsaturated rings having aromatic clyl
,
membered heteroaryl, 4-10 membered heterocy
character (i.e., having (4n + 2 ) delocalized or (pi) electrons 25 clyl, 5-10
C6-10
aryl-C1-4 alkyl, C3-10 carbocyclyl-C1-4 alkyl,
where n is an integer ).
(5-10 membered heteroaryl)-C1-4 alkyl and (4-10 membered
The term " carbocyclyl” includes a cyclic aliphatic group heterocyclyl
)-C1-4 alkyl is optionally substituted with 1, 2 , 3 ,
which may be saturated or unsaturated . For example, car 4 , or 5 substituents
independently selected from C1-4 alkyl,
bocyclyl groups include cyclopropyl, cyclopentyl, cyclo
hexyl, cycloheptyl, and cyclooctyl. In some embodiments , 30 NRCARd4
C1- haloalkyl
, halo , ,CN ,OCOR24
, SR44
, C((OO))NRCANR44
R64, C ( O ,)
, COORA4
(O )R54
, OC

carbocyclyls have from 3-8 carbon atoms in their ring
structure , for example, they can have 3 , 4 , 5 or 6 carbons in
the ring structure .
In general, the term “ aryl” includes groups, including 5
and 6 -membered single -ring aromatic groups, such as ben- 35
zene and phenyl. Furthermore, the term “ aryl” includes
multicyclic aryl groups, e.g. , tricyclic , bicyclic , such as
naphthalene and anthracene .
The term “ heteroaryl” includes groups, including 5- and
6 -membered single-ring aromatic groups, that have from 40
one to four heteroatoms, for example, pyrrole, furan , thio
phene, thiazole , isothiaozole, imidazole, triazole , tetrazole ,
pyrazole , oxazole , isooxazole , pyridine , pyraiine,
pyridazine , and pyrimidine , and the like . Furthermore , the
term " heteroaryl” includes multicyclic heteroaryl groups, 45
e.g., tricyclic , bicyclic, such as benzoxazole, benzodiox

wherein said C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl, is
optionally substituted with 1, 2 , or 3 substituents indepen

dine , indole, benzofuran , purine, benzofuran , quinazoline ,

agent.

NR NR 14 NRCAC (O )R 64, NR 4C (O )NR 4Rd4 NR 4C (0 )
ORC4, Ce= NRe4)NRAR44, NRCACE= NR®4)NRARd4, S (O )
Rb4, S (O )NRC4R04, S(O ),Rb4, NRC+S (O )_Rb4, NRAS (O )2
NRC4R14 and S (O )2NRC4Rd4;
each Ra4,Rb4,RC4 and Rd4 is independently selected from
H , C -4 alkyl, C -4 haloalkyl, C2-4 alkenyl and C2-4 alkynyl ,
dently selected from OH , CN , amino , halo, C1-4 alkyl, C1-4
alkoxy ,C1-4 alkylthio , C1-4 alkylamino , di(C1-4 alkyl)amino ,
C -4 haloalkyl, and C -4 haloalkoxy .
Where substituent groups are specified by their conven
tional chemical formulas, written from left to right, they
equally encompass the chemically identical substituents that

would result from writing the structure from right to left, for

example, CH2O– is equivalent to OCH2— . In some
azole
,
benzothiazole
,
benzoimidazole
,
benzothiophene
,
methylenedioxyphenyl, quinoline , isoquinoline , napthyri embodiments, one or more substituents can be a group
50
deazapurine , indazole, or indolizine.
The term " heterocyclyl” includes non -aromatic groups,
including but not limited to , 3- to 10 -membered single or
multiple non -aromatic rings having one to five heteroatoms,
for example , oxetane, piperazine, pyrrolidine, piperidine, or
homopiperazine.
55
The term “ substituted ” means that an atom or group of
atoms replaces hydrogen as a “ substituent” attached to
another group . For aryl and heteroaryl groups , the term

reactive with a biologically active molecule or a detectable

As used herein , chemical structures which contain one or
more stereocenters depicted with dashed and bold bonds

(i.e., 1) are meant to indicate absolute stereochemistry of

the stereocenter(s ) present in the chemical structure. As used
herein , bonds symbolized by a simple line do not indicate a
stereo -preference . Unless otherwise indicated , chemical
structures, which include one or more stereocenters , illus
trated herein without indicating absolute or relative stereo
“ substituted ” , unless otherwise indicated , refers to any level chemistry encompass all possible stereoisomeric forms of
of substitution , namely mono, di, tri, tetra , or penta substi- 60 the compound (e.g., diastereomers , enantiomers) and mix
tution , where such substitution is permitted . The substituents tures thereof ( e.g., racemic mixtures ). Structures with a
are independently selected , and substitution may be at any single bold or dashed line , and at least one additional simple
chemically accessible position . In some cases , two sites of line , encompass a single enantiomeric series of all possible
substitution may come together to form a 3-10 membered diastereomers .
65
carbocyclyl or heterocyclyl ring.
Resolution of racemic mixtures of compounds can be
Substituents include, but are not limited to , Cy ?, C1-6 carried out by any of numerous methods known in the art.
alkyl, C2-6 alkenyl, C2-6 alkynyl, halo , C1-6 haloalkyl, CN , An exemplary method includes fractional recrystallization
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using a chiral resolving acid which is an optically active , base or acid in water or in an organic solvent, or in a mixture
salt -forming organic acid . Suitable resolving agents for of the two; in some embodiments , a non- aqueous media like
fractional recrystallization methods are , for example , opti
ether, ethyl acetate , alcohols ( e.g., methanol, ethanol, iso
cally active acids, such as the D and L forms of tartaric acid , propanol, or butanol) or acetonitrile (ACN ) can be used .
diacetyltartaric acid , dibenzoyltartaric acid , mandelic acid , 5 Lists of suitable salts are found in Remington's Pharmaceu
malic acid , lactic acid , or the various optically active cam
tical Sciences, 17th ed .,Mack Publishing Company, Easton ,
phorsulfonic acids such as camphorsulfonic acid . Other Pa ., 1985, p . 1418 and Journal of Pharmaceutical Science ,

resolving agents suitable for fractional crystallization meth
ods include stereoisomerically pure forms of methylben

66 , 2 ( 1977 ). Conventionalmethods for preparing salts are
described , for example, in Handbook of Pharmaceutical

organic acids. The pharmaceutically acceptable salts of the

tion to be treated or the cosmetic purpose , e.g., at a reason

prepared by reacting the free acid or base forms of these
compounds with a stoichiometric amount of the appropriate

clinical signs , and underlying pathology of a condition in
manner to improve or stabilize a patient's condition .

zylamine ( e.g., S and R forms, or diastereomerically pure 10 Salts : Properties, Selection , and Use , Wiley -VCH , 2002 .
forms), 2 -phenylglycinol, norephedrine, ephedrine , N -meth
The term “ essentially pure” refers to chemical purity of a
ylephedrine, cyclohexylethylamine, 1,2 - diaminocyclo
compound provided herein that may be substantially or
hexane, and the like.
essentially free of other components which normally accom
Resolution of racemic mixtures can also be carried out by pany or interact with the compound prior to purification . By
elution
on a column packed with an optically active resolv- 15 way of example only , a compound may be “ essentially pure”
ing agent ( e.g., dinitrobenzoylphenylglycine). Suitable elu when the preparation of the compound contains less than
tion solvent compositions can be determined by one skilled about 30 % , less than about 25 % , less than about 20 % , less
in the art.
than about 15 % , less than about 10 % , less than about 5 % ,
The phrase “ pharmaceutically acceptable ” is employed less than about 4 % , less than about 3 % , less than about 2 % ,
herein to refer to those compounds, materials , compositions, 20 or less than about 1 % (by dry weight) of contaminating
and/or dosage formswhich are, within the scope of sound components . Thus, an “ essentially pure” compound may
medical judgment, suitable for use in contact with the tissues have a purity level of about 70 % , about 75 % , about 80 % ,
of human beings and animals without excessive toxicity , about 85 % , about 90 % , about 95 % , about 96 % , about 97 % ,
irritation , allergic response , or other problem or complica about 98 % , about 99 % or greater. For the purposes of this
tion , commensurate with a reasonable benefit/ risk ratio . 25 document, preparations of functionalized polymers or con
The term “ salt” includes any ionic form of a compound jugates differing only in the length of their polymer chain are
and one or more counter-ionic species ( cations and /or considered to be essentially pure. An essentially pure com
anions). Salts also include zwitterionic compounds ( i.e., a pound may be obtained using chromatographic purification
molecule containing one more cationic and anionic species , methods.
e.g., zwitterionic amino acids ). Counter ions present in a salt 30 As used herein , “ amphiphilic ” or “ amphiphile” refers to a
can include any cationic , anionic , or zwitterionic species . chemical compound possessing regions of very different
Exemplary anions include, but are not limited to : chloride, properties in termsof preferred solvation or association with
bromide, de , nit te, sulfate , bisulfate , sulfite , bisulfite , a liquid interface or a solid surface . The most common
phosphate , acid phosphate, perchlorate, chlorate, chlorite, examples of amphiphiles possess both hydrophilic (water
hypochlorite , periodate , iodate, iodite , hypoiodite, carbon- 35 loving , polar) and lipid (fat-loving , non -polar ) properties .
ate, bicarbonate , isonicotinate , acetate, trichloroacetate, tri Generally, amphiphilic compounds herein have a polar
fluoroacetate , lactate , salicylate, citrate , tartrate , pantothen
region on one half or terminal portion of the compound and
ate , bitartrate , ascorbate , succinate , maleate , gentisinate, a non -polar region at the opposite half or terminal portion of
fumarate, gluconate, glucaronate , saccharate , formate , ben
the compound. Fatty acids , triglycerides, and derivatives
zoate , glutamate , methanesulfonate , trifluoromethanesul- 40 thereof are examples of amphiphilic compounds. An
fonate , ethanesulfonate , benzenesulfonate , p - toluenesul example of another class of amphiphiles are molecules
fonate , p -trifluoromethylbenzenesulfonate , hydroxide , containing either a hydrophobic or hydrophiic region on one
aluminates , and borates. Exemplary cations include, but are half or terminal portion of the molecule and a thiol or similar
not limited to : monovalent alkali metal cations, such as functional group possessing high affinity for a metal on the
lithium , sodium , potassium , and cesium , and divalent alka- 45 other half or terminus.
line earth metals, such as beryllium , magnesium , calcium ,
“ Fatty acid derivatives” as used herein refer to com
strontium , and barium . Also included are transition metal pounds having a fatty acid hydrocarbon backbone, but
cations, such as gold , silver, copper and zinc , as well as which may be optionally substituted as provided herein . In
non -metal cations, such as ammonium salts .
addition , a fatty acid derivative may have the carboxylic acid
Also provided herein are pharmaceutically acceptable 50 functional group replaced with another reactive group , for
salts of the compounds described herein . As used herein , example , a hydroxyl group , an ester group, an aldehyde
" pharmaceutically acceptable salts” refers to derivatives of group , a carboxyl group , a sulfhydryl group , an amine
the disclosed compounds wherein the parent compound is group , an amide group, a carbamide group , or a phosphate
modified by converting an existing acid or base moiety to its group .
salt. Examples of pharmaceutically acceptable salts include, 55 A “ therapeutically effective amount” of a compound with
but are not limited to , mineral or organic acid salts of basic respect to the subject method of treatment, refers to an
residues such as amines; alkali or organic salts of acidic amount of the compound (s) in a preparation which , when
residues such as carboxylic acids , and the like . The phar administered as part of a desired dosage regimen ( to a
maceutically acceptable salts of the compounds provided patient, e.g., a human ) alleviates a symptom , ameliorates a
herein include the conventional non - toxic salts of the parent 60 condition , or slows the onset of disease conditions according
compound formed , for example , from non - toxic inorganic or to clinically acceptable standards for the disorder or condi

compounds provided herein can be synthesized from the able benefit/ risk ratio applicable to any medical treatment.
parent compound which contains a basic or acidic moiety by
As used herein , the term “ treating” or “ treatment”
conventional chemical methods.Generally, such salts can be 65 includes reversing, reducing , or arresting the symptoms,
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Antimicrobial Agents
Provided herein are amphiphilic compounds containing a

In some embodiments , at least one of R² or R4 is a C7 -C40
alkyl. For example , if R * is H , then R ’ is a C , -C40 alkyl ( e.g.,
cyclobutane or cyclobutene moiety . For example, amphiphi Cs- C20 alkyl, C16C30 alkyl, and C2- C , alkyl), or if R3 is
lic acids, alcohols, esters, thiols, amides, or related groups absent, then R * is C , -C40 alkyl (e.g., C5-C20 alkyl, C10C30
incorporating within their backbone a four-membered ring 5 alkyl, and C2- C , alkyl). In some embodiments, R ’ is a
carbocycle ( cyclobutane, cyclobutene , cyclobutanone, or C7 -C10 alkyl. For example , Rº can be a C , alkyl. In some
embodiments , R4 is a C ,-C10 alkyl. For example, R * can be
substituted derivatives ).
A compound provided herein can include a compound of a Cg alkyl. In some embodiments, R4 is H. R3 and R4 can be
independently optionally substituted. For example , substitu
Formula (I):
10
ents include , but are not limited to , Cy ?, C1-6 alkyl, C2-6
alkenyl
, C2-6 alkynyl , halo , C1-6 haloalkyl, CN , NO2, ORal,
R!
R2
SR " , CORT, C (O )NRC?R " , C (O )ORCI, OC (O )R51,
Rd , NR CENRel)
OC (O )NRCIRDI, CENREINR
CENRI)NRCIRI
1

15

R4

R3 - Z

NRCIRI,NRC'RI,NRCIC (O )R1, NRCIC (O )ORI, NRC
(O )NRCIRPI, NR IS(ORI, NRCS(O ),R51, NRC'S (O )2
NRCIR I, S (O )RI, S (O )NRCIR ( I, S (O ), R0l and S (O ),
NRCIRDI.

or a pharmaceutically acceptable salt thereof,
each Cyl is independently C6-10 aryl, C3-10 carbocyclyl,
wherein :
20 5-10 membered heteroaryl or 4-10 membered heterocyclyl,
represents an optionally present double bond;
each of which is unsubstituted or substituted by 1 , 2, 3, 4 or
R1 and R2 are independently selected from the group con
5 substituents independently selected from C1-6 alkyl, C2-6
sisting of: H , halo , OR , and = 0 ;
alkenyl, C2- alkynyl, halo , CN , NO , ORCI, SRal, C (O )Rhi

R is absent or is an optionally substituted C ,-C40 alkyl;
C (O )NRCROI, COOR , OCOR , OC(O )NRCÍrdi,
R * is H or an optionally substituted C ,-C40 alkyl; and
25 CCNRel) NRclRd , NRCC_NR® NRclRdì , NRC Rd.
Z is selected from the group consisting of: CORO, COR", NRICOR61, NRC COORI, NR - C (O )NRIRI,NR'S
NHC (O )NROR ”, CONR ”, OCOR , OR®, SR “, NRÓR ?, (O )R51,NRCIS (O ), Rb1, NRCIS(O )2NRCIRI, S (O )R51, S (O )

NRCIR I, S (O ),R1, S (O ),NRCIR and oxo ;
each Ral, Roí, Rei, Rdi,is independently selected from H ,
30 C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10
R and R7 are independently H or C ,-C . alkyl;
wherein the hydrocarbon backbone formed by R4 and R3- Z aryl, C3-10 carbocyclyl, 5-10 membered heteroaryl, 4-10
membered heterocyclyl, C6-10 aryl-C1-4 alkyl, C3-10 carbo
is amphiphilic
-C1-4 alkyl, (5-10 membered heteroaryl )-C1-4 alkyl or
In some embodiments , the compound of Formula (I) is cyclyl
(4-10 membered heterocyclyl) -C1-4 alkyl, wherein said C1-6
not:
35 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 carbocy
clyl, 5-10 membered heteroaryl, 4-10 membered heterocy
clyl, C6-10 aryl-C14 alkyl, C3-10 carbocyclyl-C1-4 alkyl,
(5-10 membered heteroaryl)-C1-4 alkyl and (4-10 membered
heterocyclyl)-C1-4 alkyl is optionally substituted with 1 , 2 , 3 ,
40 4, or 5 substituents independently selected from C1-4 alkyl ,
C -4 haloalkyl, halo , CN , ORC4, SR44, C ( O ) R 64, C (O )
NR 4R04 , C (O )OR4, OC (O )R64 , OC (O )NR 4Rd4,NRC4R04,

and OPO , R ;
Ris H or C.-C. alkyl;

or

NRC4C (O )Rb4 NRCAC (C (O )NRCARd4 , NRC4C (O )OR24,
CENR )NRC4R14, NRACENR®4)NR 4R04, SO64,
45 S (O )NRC4R04, S ( O ) Rb4 , NRC4S (O ) 2Rb4 , NRC4S (O )2
NRC4Rd4 and S (O )2NRCARd4;
each R24, Rb4,RCA and Rd4 is independently selected from
H , C -4 alkyl, C -4 haloalkyl, C2-4 alkenyl and C2-4 alkynyl ,
wherein said C.4 alkyl, C2-4 alkenyl, and C2.4 alkynyl, is
50 optionally substituted with 1, 2 , or 3 substituents indepen
dently selected from OH , CN , amino , halo , C1-4 alkyl , C1-4
alkoxy, C1-4 alkylthio , C1-4 alkylamino , di(C1-4 alkyl)amino ,
C1-4 haloalkyl, and C1-4 haloalkoxy.
In some embodiments, the substituents can be selected
55 from the group consisting of an alkyl, a halogen , a hydroxyl,
an alkoxyl, a carbonyl (such as a carboxyl, an alkoxycar

bonyl, a formyl, or an acyl), a thiocarbonyl (such as a

thioester, a thioacetate , or a thioformate ), an alkoxyl, a
phosphoryl, a phosphate , a phosphonate , a phosphinate, an
60 amino, an amido , an amidine , an imine , a cyano, a nitro , an
azido , a suithydryl, an alkylthio , a sulfate , a sulfonate , a
sulfamoyl , a sulfonamido, a sulfonyl , a carbocyclyl, a het
erocyclyl, an aralkyl, a heteroaralkyl, or an aromatic or
heteroaromatic moiety .
65
In some embodiments, Z is COR®.
In some embodiments , R ' and R are independently
A compound provided herein can be selected from the
selected from the group consisting of: H , halo , OH and = O . group consisting of:
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-continued
HO
5

R4

R3—2 R4
?? .

R4

R3—2

R4

R3 — Z

R4

R3 — Z R4

R3—2

R3 - Z

R3—2

R4

R3 — Z

R4

10
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or a pharmaceutically acceptable salt thereof, wherein R3,
R4 and Z are as described previously .
In some embodiments , a compound provided herein is a 20

compound of Formula (II):
R2

R

25

Polls

(CH2) 7CO2H

( CH2)7CO2H

OH

( CH2)7CO2H

(CH2)7CO2H

or a pharmaceutically acceptable salt thereof.
In some embodiments , a compound provided herein can
be selected from the group consisting of:

A

C4H8

( CH2) 7CO2H

C4H8

C3H8

alloon

(CH2)7CO2H

CgHj8

( CH2)7C02H

C8H8

( CH2)7CO2H

C8H8

(CH2)7CO2H

(CH2)7CO2H

R3 - Z

or a pharmaceutically acceptable salt thereof, wherein R ',

30

OH

?? .

R ?, R3, R4 and Z are as described previously. In some
embodiments, a compound provided herein is a compound

of Formula (III ):

C8H18

(CH2)7C02H

(CH2) 7CO2H

C3H18

(CH2)7CO2H

(CH2)7CO2H

C3H18

(CH2)7CO2H

C8H18

( CH2)7CO2H

C3H18

ll.
CgHì8

35

O

R2

R!

40

R3 — Z

R4

or a pharmaceutically acceptable salt thereof, wherein R ' ,
R2, R3, R4 and Z are as described previously .

HO

Non -limiting examples of a compound provided herein 45
includes:
(CH2)7C02H

(CH2)7C02H

50

C3H18

(CH2)7CO2H

C8H18

( CH2)7CO2H
( CH2)7CO2H
55

C3H18

C8H18

(OH
CH2) 7CO2H

(CH2)7CO2H

X

C3H8

C8H18
?? .

C8H18

(CH2)7CO2H

C3H8

or a pharmaceutically acceptable salt thereof.
Pharmaceutical Compositions and Dosage Forms

When employed as pharmaceuticals, the compounds pro

(CH2) 7CO2H
Ci

(CH2)7CO2H

(CH2)7CO2H

( CH2)7C02H

vided herein can be administered in the form of pharma
60 ceutical compositions. These compositions can be prepared
in a manner well known in the pharmaceutical art , and can
be administered by a variety of routes , depending upon
whether local or systemic treatment is desired and upon the
area to be treated . Administration may be topical ( including
65 transdermal, epidermal, ophthalmic and to mucous mem
branes including intranasal, vaginal and rectal delivery) ,
pulmonary (e.g., by inhalation or insufflation of powders or
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aerosols, including by nebulizer; intratracheal or intranasal), can be readily subdivided into equally effective unit dosage
oral or parenteral. Parenteral administration includes intra
forms such as tablets , pills and capsules . This solid prefor
venous, intraarterial, subcutaneous, intraperitoneal, intra mulation is then subdivided into unit dosage forms of the
muscular or injection or infusion ; or intracranial, e.g., type described above containing from , for example , about
intrathecal or intraventricular , administration . Parenteral 5 0.1 to about 1000 mg of the active ingredient provided
administration can be in the form of a single bolus dose , or herein .
may be, for example , by a continuous perfusion pump .
The tablets or pills provided herein can be coated or
Pharmaceutical compositions and formulations for topical otherwise compounded to provide a dosage form affording
administration may include transdermal patches, ointments, the advantage of prolonged action . For example, the tablet or
lotions, creams, gels , drops, suppositories, sprays, liquids 10 pill can comprise an inner dosage and an outer dosage
and powders . Conventional pharmaceutical carriers, aque component, the latter being in the form of an envelope over
ous, powder or oily bases , thickeners and the like may be the former. The two components can be separated by an
necessary or desirable .
enteric layer which serves to resist disintegration in the
This disclosure also provides pharmaceutical composi stomach and permit the inner component to pass intact into
tions which contain , as the active ingredient, a compound 15 the duodenum or to be delayed in release . A variety of
provided herein or a pharmaceutically acceptable salt materials can be used for such enteric layers or coatings,
thereof, in combination with one or more pharmaceutically such materials including a number of polymeric acids and
acceptable carriers (excipients ). In some embodiments , the mixtures of polymeric acids with such materials as shellac ,
composition is suitable for topical administration . In making cetyl alcohol, and cellulose acetate .
the compositions provided herein , the active ingredient is 20 The liquid forms in which the compounds and composi
typically mixed with an excipient, diluted by an excipient or tions provided herein can be incorporated for administration
enclosed within such a carrier in the form of, for example , orally or by injection include aqueous solutions, suitably
a capsule , sachet, paper, or other container. When the flavored syrups , aqueous or oil suspensions, and flavored
excipient serves as a diluent, it can be a solid , semi- solid , or emulsions with edible oils such as cottonseed oil , sesame oil ,
liquid material, which acts as a vehicle , carrier or medium 25 coconut oil, or peanut oil, as well as elixirs and similar
for the active ingredient. Thus, the compositions can be in pharmaceutical vehicles .
the form of tablets, pills , powders, lozenges , sachets,
In some embodiments , the compounds provided herein
cachets, elixirs, suspensions, emulsions, solutions, syrups, are for nulated for intravenous administration. Pharmaceu
aerosols (as a solid or in a liquid medium ), ointments tical compositions suitable for injectable use can include
containing, for example, up to 10 % by weight of the active 30 sterile aqueous solutions (where water soluble) or disper
compound, soft and hard gelatin capsules, suppositories , sions and sterile powders for the extemporaneous prepara
sterile injectable solutions, and sterile packaged powders. tion
of sterile injectable solutions
or dispersion . For intra
suitable carriers include
In preparing a formulation , an active compound can be venous adminis
milled to provide the appropriate particle size prior to physiological saline, bacteriostatic water, Cremophor ELTM
combining with the other ingredients . If an active compound 35 (BASF , Parsippany, N.J. ) or phosphate buffered saline
is substantially insoluble , it can be milled to a particle size (PBS). In all cases, the composition must be sterile and
of less than 200 mesh . If an active compound is substantially should be fluid to the extent that easy syringability exists. It
water soluble , the particle size can be adjusted by milling to should be stable under the conditions of manufacture and
provide a substantially uniform distribution in the formula
storage and must be preserved against the contaminating
tion , e.g. about 40 mesh .
40 action of microorganisms such as bacteria and fungi . The
The compounds provided herein may be milled using carrier can be a solvent or dispersion medium containing , for
known milling procedures such as wet milling to obtain a example , water, ethanol, polyol ( for example , glycerol,
particle size appropriate for tablet formation and for other propylene glycol, and liquid polyethylene glycol, and the
formulation types. Finely divided (nanoparticulate) prepa like ), and suitable mixtures thereof. The proper fluidity can
rations of the compounds provided herein can be prepared 45 be maintained , for example, by the use of a coating such as
by processes known in the art , e.g., see International App . lecithin , by the maintenance of the required particle size in
No. WO 2002/000196 .
the case of dispersion and by the use of surfactants. Pre
Some examples of suitable excipients include lactose, vention of the action ofmicroorganisms can be achieved by
dextrose , sucrose, sorbitol, mannitol, starches, gum acacia , various antibacterial and antifungal agents, for example,
calcium phosphate , alginates, tragacanth , gelatin , calcium 50 parabens, chlorobutanol, phenol, ascorbic acid , thimerosal,
silicate , microcrystalline cellulose, polyvinylpyrrolidone , and the like. In many cases , it will be preferable to include
cellulose , water, syrup , and methyl cellulose . The formula
isotonic agents , for example , sugars, polyalcohols such as
tions can additionally include : lubricating agents such as mannitol, sorbitol, sodium chloride in the composition .
talc , magnesium stearate , and mineral oil; wetting agents ; Prolonged absorption of the injectable compositions can be
emulsifying and suspending agents ; preserving agents such 55 brought about by including in the composition an agent that
as methyl- and propylhydroxy -benzoates ; sweetening delays absorption , for example , aluminum monostearate and
agents; and flavoring agents . The compositions provided gelatin .
herein can be formulated so as to provide quick , sustained or
Sterile injectable solutions can be prepared by incorpo
delayed release of the active ingredient after administration rating the active compound in the required amount in an
to the patient by employing procedures known in the art. 60 appropriate solvent with one or a combination of ingredients
For preparing solid compositions such as tablets, the enumerated above, as required , followed by filter steriliza
principal active ingredient is mixed with a pharmaceutical tion . Generally, dispersions are prepared by incorporating
excipient to form a solid preformulation composition con the active compound into a sterile vehicle, which contains a
taining a homogeneous mixture of a compound provided basic dispersion medium and the required other ingredients
herein . When referring to these preformulation compositions 65 from those enumerated above. In the case of sterile powders
as homogeneous , the active ingredient is typically dispersed for the preparation of sterile injectable solutions, the pre
evenly throughout the composition so that the composition ferred methods of preparation are vacuum drying and freeze
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drying, which yield a powder of the active ingredient plus
any additional desired ingredient from a previously sterile
filtered solution thereof.
Compositions for inhalation or insufflation include solu
tions and suspensions in pharmaceutically acceptable , aque- 5
ous or organic solvents , or mixtures thereof, and powders .
The liquid or solid compositions may contain suitable phar
maceutically acceptable excipients as described supra . In
some embodiments, the compositions are administered by
the oral or nasal respiratory route for local or systemic effect. 10
Compositions can be nebulized by use of inert gases. Nebu
lized solutions may be breathed directly from the nebulizing
device or the nebulizing device can be attached to a face
mask , tent, or intermittent positive pressure breathing
machine. Solution , suspension , or powder compositions can 15
be administered orally or nasally from devices which deliver
the formulation in an appropriate manner .
Topical formulations can contain one or more conven
tional carriers . In some embodiments, ointments can contain

16

discrete units suitable as unitary dosages for human subjects
and other mammals, each unit containing a predetermined
quantity of active material calculated to produce the desired
therapeutic effect , in association with a suitable pharmaceu
tical excipient.
In some embodiments, the compositions provided herein
contain from about 5 to about 50 mg of the active ingredient.
One having ordinary skill in the art will appreciate that this
embodies compositions containing about 5 to about 10 ,
about 10 to about 15, about 15 to about 20 , about 20 to about
25, about 25 to about 30 , about 30 to about 35, about 35 to
about 40 , about 40 to about 45 , or about 45 to about 50 mg
of the active ingredient.
In some embodiments , the compositions provided herein
contain from about 50 to about 500 mg of the active
ingredient. One having ordinary skill in the art will appre
ciate that this embodies compositions containing about50 to
about 100 , about 100 to about 150 , about 150 to about 200 ,
about 200 to about 250 , about 250 to about 300 , about 350

water and one or more hydrophobic carriers selected from , 20 to about 400 , or about 450 to about 500 mg of the active
for example, liquid paraffin , polyoxyethylene alkyl ether , ingredient.
propylene glycol, white Vaseline , and the like. Carrier
In some embodiments , the compositions provided herein
compositions of creams can be based on water in combina
contain from about 500 to about 1000 mg of the active
tion with glycerol and one or more other components , e.g. ingredient. One having ordinary skill in the art will appre

glycerinemonostearate , PEG -glycerinemonostearate and 25 ciate that this embodies compositions containing about 500

cetylstearyl alcohol. Gels can be formulated using isopropyl
alcohol and water, suitably in combination with other com
ponents such as, for example , glycerol, hydroxyethyl cellu
lose , and the like . In some embodiments , topical formula
tions contain at least about 0.1 , at least about 0.25 , at least 30
about 0.5 , at least about 1 , at least about 2 , or at least about

5 wt % of the compound provided herein . The topical
formulations can be suitably packaged in tubes of, for
example , 100 g which are optionally associated with instruc
tions for the treatment of the select indication .
35
In one embodiment, the compounds provided herein are
prepared with carriers that will protect the compounds
against rapid elimination from the body, such as a controlled
release formulation , including implants and microencapsu
lated delivery systems. Biodegradable, biocompatible poly- 40
mers can be used , such as ethylene vinyl acetate, polyan
hydrides , polyglycolic acid , collagen , polyorthoesters, and
polylactic acid. Such formulations can be prepared using
standard techniques, or obtained commercially , e.g. , from
Alza Corporation and Nova Pharmaceuticals , Inc. Lipo- 45
somal suspensions (including liposomes targeted to selected
cells with monoclonal antibodies to cellular antigens) can
also be used as pharmaceutically acceptable carriers. These
can be prepared according to methods known to those
skilled in the art, for example, as described in U.S. Pat. No. 50
4,522,811.

The compositions administered to a patient can be in the
form of pharmaceutical compositions described above .
These compositions can be sterilized by conventional ster
ilization techniques, or may be sterile filtered . Aqueous 55
solutions can be packaged for use as is, or lyophilized , the
lyophilized preparation being combined with a sterile aque
ous carrier prior to administration . The pH of the compound
preparations typically will be between 3 and 11 , more
preferably from 5 to 9 and most preferably from 7 to 8. It 60
will be understood that use of certain of the foregoing
excipients, carriers, or stabilizers will result in the formation
of pharmaceutical salts .
The compositions can be formulated in a unit dosage
form , each dosage containing from about 5 to about 1000 mg 65
( 1 g ), more usually about 100 to about 500 mg, of the active
ingredient. The term " unit dosage forms” refers to physically

to about 550 , about 550 to about 600 , about 600 to about
650 , about 650 to about 700 , about 700 to about 750 , about
750 to about 800 , about 800 to about 850 , about 850 to about
900, about 900 to about 950 , or about 950 to about 1000 mg
of the active ingredient.
Similar dosages may be used of the compounds described

herein in the methods and uses provided herein .
The active compound can be effective over a wide dosage
range and is generally administered in a pharmaceutically
effective amount. It will be understood , however, that the
amount of the compound actually administered will usually
be determined by a physician , according to the relevant
circumstances , including the condition to be treated , the
chosen route of administration , the actual compound admin
istered , the age, weight, and response of the individual
patient, the severity of the patient's symptoms, and the like.
The amount of compound or composition administered to
a patientwill vary depending upon what is being adminis
tered , the purpose of the administration , such as prophylaxis
or therapy , the state of the patient, the manner of adminis
tration , and the like. In therapeutic applications, composi
tions can be administered to a patient already suffering from
a disease in an amount sufficient to cure or at least partially
arrest the symptoms of the disease and its complications .
Effective doses will depend on the disease condition being
treated as well as by the judgment of the attending clinician
depending upon factors such as the severity of the disease ,
the age, weight and general condition of the patient, and the
like .
The therapeutic dosage of a compound provided herein
can vary according to , for example , the particular use for
which the treatment is made, the manner of administration
of the compound , the health and condition of the patient,and
the judgment of the prescribing physician . The proportion or
concentration of a compound provided herein in a pharma
ceutical composition can vary depending upon a number of
factors including dosage , chemical characteristics (e.g.,
hydrophobicity ), and the route of administration . For
example , the compounds provided herein can be provided in
an aqueous physiological buffer solution containing about
0.1 to about 10 % w /v of the compound for parenteral
administration . Some typical dose ranges are from about 1
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mg/kg to about 1 g /kg of body weight per day. In some
Mycobacterium nonchromogenicum /terrae clade include ,
embodiments, the dose range is from about 0.01 mg/kg to for example , M. hiberniae, M. nonchromogenicum , M. ter
about 100 mg/ kg of body weight per day. The dosage is rae, M. triviale , and Mycolactone -producing mycobacteria ;
likely to depend on such variables as the type and extent of
Mycobacterium simiae clade include, for example , M.
progression of the disease or disorder, the overall health 5 triplex
, M. florentinum , M. lentiflavum , M.
status of the particular patient, the relative biological effi palustre, ,M.M.genavense
kubicae
,
, M. heidelber
cacy of the compound selected, formulation of the excipient, gense, M. interjectum ,M.andparascrofulaceum
M.
simiae
;
and its route of administration . Effective doses can be

extrapolated from dose -response curves derived from in

vitro or animal model test systems.
Methods of Use

Mycobacterium chelonae clade include, for example , M.

10 abscessus, M. chelonae , and M. bolletii ;

Mycobacterium fortuitum clade include, for example, M.
The compounds provided herein can be used as antibac fortuitum
fortuitum , M. boenickei , M. peregrinum , M.
terial agents, in particular, antimycobacterialagents. In some porcinum ,, M.
M.
senegalense, M. septicum , M. newor
embodiments, the bacterial infection is a Gram - positive leansense, M. houstonense
M. mucogenicum , M. mager
organism that either uptakesmycolic acid , usesmycolic acid 15 itense , M. brisbanense , and, M.
cosmeticum ;
in a biosynthetic process , synthesizes mycolic acid , or
requires mycolic acid as a nutritional supplement. For
Mycobacterium parafortuitum clade include, for example ,
example , the compounds provided herein can used to treat a M. parafortuitum , M. austroafricanum , M. diernhoferi, M.
patient infected with a mycobacterium . In some embodi hodleri, M. neoaurum , and M. frederiksbergense;
ments, the compounds provided herein can inhibit the 20 Mycobacterium vaccae clade include , for example, M.
growth of a mycobacterium (e.g., Mycobacterium tubercu
losis ). Accordingly, provided herein is a method for treating aurum and M. vaccae;
CF include, for example, M. chitae and M. fallax.
a mycobacterial infection in a mammal comprising admin
istering a therapeutically effective amount of a compound
Additional examples of mycobacterium include, for
provided herein .
25 example, M. branderi, M. cookie, M. celatum , M. bohemi
Without being bound by any theory, the compounds cum , M. haemophilum , M. malnloense, M. szulgai, M.
provided herein are thought to function through selective leprae , M. lepraemurium , M. lepromatosis, M. africanum ,
inhibition or activation of biological processes that would
botniense, M.chimaera , M. conspicuum , M.doricum , M.
normally process fatty acids, esters, alcohols . In some M.
farcinogenes
, M. heckeshornense, M. intracellulare, M.
embodiments, the compoundsmay function as competitive 30 lacus, M. marinum
, M. monacense, M. montefiorense , M.
or irreversible inhibitors based upon their inclusion of, for murale, M.nebraskense
, M. saskatchewanense, M. scrofu
example , a strained four-membered ring moiety . By way of laceum , M. shimoidei, M.
tusciae , M. xenopi, M.ulcerans,
example, certain mycolic acids are found in the cell wall of M.
pseudoshottsii
,
M.
shottsii
confluentis , M.flavescens,
M. tuberculosis; in particular , a -mycolic acid , which incor M.madagascariense, M.phlei, ,M.
smegmatis, M. goodii, M.
porates two cyclopropane rings . The presence of cyclopro- 35 wolinskyi, M.thermoresistibile,M.
M.
, M. komossense,
panes are thought to contribute to the structural integrity of M. obuense, M. sphagni, M.agri, M.gadium
aichiense
, M.alvei , M.
the cell wall and protect the vacillus from oxidative stress arupense , M. brumae , M. canariasense, M. chubuense
inside macrophages. Mycolic acids are assembled in myco conceptionense , M. duvalii, M. elephantis , M. gilvum ,, M.
M.
bacteria from shorter - chain fatty acid feedstocks. The com hassiacum , M. holsaticum , M. immunogenum , M. massil
pounds provided herein can be taken up into the bacteria my 40 iense , M. moriokaense , M. psychrotolerans, M. pyreniv
mimicking these feed stocks and can , for example , disrupt orans
vanbaalenii, M. pulveris , M. arosiense , M. auba
mycolic acid biosynthesis through the presence of their gnense, ,M. M.
M.
caprae, M. chlorophenolicum
strained four-membered ring moieties .
fluoroanthenivorans
,
M.
kumamotonense
,
M.
novocastrense
Mycobacterium include, for example, bacteria which are M.parmense, M.phocaicum , M. poriferae , M. rhodesiae, M.,
members
of the MTBC
Mycobacterium
tubercu- 45 seoulense, M.tokaiense , and M. intermedium .
losis complex
( groups)including
, Mycobacterium
avium complex
In some embodiments , the mycobacterium is a member of
(MAC ), Mycobacterium gordonae clade, Mycobacterium
kansasii clade , Mycobacterium nonchromogenicum / terrae MTBC . For example, M. tuberculosis, the major cause of
clade, Mycolactone -producing mycobacteria, Mycobacte human tuberculosis, M.bovis, M. bovis BCG , M. avium . In
rium simiae clade, Mycobacterium chelonae clade, Myco- 50 some embodiments, the mycobacterium is M. tuberculosis .
bacterium fortuitum clade,Mycobacterium fortuitum clade , In some embodiments , the mycobacterium is M. bovis . In
embodiments, the mycobacterium is M. avium sub
Mycobacterium parafortuitum clade, Mycobacterium vac some
species paratuberculosis.
cae clade, and CF.
For example , each of the groups include the following
In some embodiments , one or more compounds provided
bacteria as members :

55 herein are administered with another antibiotic useful for

Mycobacterium tuberculosis complex (MTBC) include,
for example, M. tuberculosis, M. bovis , M. bovis BCG , M.
africanum , M. canetti, M. caprae, M. microti, and M.
pinnipedii ;
Mycobacterium avium complex (MAC ) include , for 60
example , M. avium , M.avium paratuberculosis , M. avium
silvaticum , M. avium “ hominissuis” , M. colombiense , and
M. indicus pranii,
Mycobacterium gordonae clade include, for example , M.

treating mycobacterial infections. These additional antibiot
ics may include : ethambutol, isoniazid , pyrazinamide,mem
bers of the rifamycin class ( including, for example, rifam
picin ), aminoglycosides ( for example , amikacin or
kanamycin ), polypeptides (for example , capreomycin , vio
mycin , or enviomycin ), fluoroquinolones (for example cip
rofloxacin levofloxacin, or moxifloxacin ), ethionamide, pro
thionamide, cycloserine , any other antibiotic employed as
part of a therapeutic treatment for mycocaterial infections,
asiaticumm and M. gordonae ;
65 and any combination of the antibiotics listed above. The
Mycobacterium kansasii clade include , for example, M. additional antibiotic can be administered before , after, or
simultaneously with a compound as provided herein .
gastri and M. kansasii;
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Amphiphilic Polymers
Certain of the compounds provided herein are can be used
as monomers to produce amphiphilic polymers . Such reac
tions can prepare a variety of polymers such as those shown
in Scheme 1 .

Scheme 1
Ph

Grubbs' I and II
OH

COOH
Ph

Grubbs' I and II
OMe

COOMe

Compounds of Formula (IV ) can be used to prepare
polymers using any number of known polymerization reac

tions. A compound of Formula (IV ) includes:

40
0

45

R4

R3 — Z

or a pharmaceutically acceptable salt thereof,

50

wherein :

R3 is absent or is an optionally substituted C1- C40 alkyl;
R4 is H or an optionally substituted C -C40 alkyl; and

Z is selected from the group consisting of: CORF , COZR “, 55
NHC( O) NR ° RY, CONR , OCOR , OR °, SR6, NR R7,
and OPOZR ";
Ris H or C.-C. alkyl;
R and R7 are independently H or C -C6 alkyl;

60

wherein the hydrocarbon backbone formed by R * and R3- Z
is amphiphilic .
In some embodiments , the compound of Formula (I) is
not:

65

or
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In some embodiments , at least one of R3 or R * is a C , -C40 thioester , a thioacetate, or a thioformate ), an alkoxyl , a
alkyl. For example , if R * is H , then R ’ is a C.-C40 alkyl (e.g., phosphoryl, a phosphate, a phosphonate , a phosphinate, an
C5-C20 alkyl, C1 -C3, alkyl, and CZ- C , alkyl), or if R * is amino, an amido , an amidine, an imine , a cyano , a nitro , an
absent, then R * is C , -C40 alkyl ( e.g., C3- C20 alkyl, C10C30 azido , a sulfhydryl, an alkylthio , a sulfate, a sulfonate , a
alkyl, and C2 - C , alkyl). In some embodiments , R3 is a 5 sulfamoyl, a sulfonamido , a sulfonyl, a carbocyclyl, a het
C1-C10 alkyl. In some embodiments, R? is a C ,-C10 alkyl. erocyclyl, an aralkyl, a heteroaralkyl, or an aromatic or
For example, Rº can be a C , alkyl. In some embodiments , R4 heteroaromatic moiety.
is a C ,-C10 alkyl. For example, R4 can be a Cg alkyl. In some
In some embodiments, the hydrocarbon backbone formed
embodiments , R4 is H. R3 and R + can be independently by R3 and R * is a fatty acid or a derivative thereof which

optionally substituted . For example , substituents include, 10
but are not limited to , Cy ', C1-6 alkyl, C2-6 alkenyl, C2-6
alkynyl, halo , C1-6 haloalkyl, CN , NO2, ORI, SRAI, C (O )
Rbi, C (O )NRCIRIT, C (O )Oral, OC (O )Rb1, OC (O )NRCIRI,
CÁNR )NRCRá , NRCICENR NRCIRI NR IRAI,

contains a cyclobutene moiety. In some embodiments, R3
and R * together with the cyclobutene moiety form a hydro
carbon chain with a reactive group at one terminus ( e.g.,
carboxylic acid or a Z moiety as defined above ). In some
embodiments, the hydrocarbon chain ranges from 10 to 30

NRC(O )R51, NRCC(O )ORI, NRCIC (O )NRCIRPI, NRCS 15 carbon atoms and may be substituted or unsubstituted .
(O )RÓI, NRCIS (O ) Rb1,NRC'S(O ) NRC?R I, S(O )R51, S (O ) Non -limiting examples include myristoleic acid , pamitoleic
9

acid , sapienic acid , oleic acid , linoleic acid , linolenic acid ,
NRCIRd1, S (O ),Rb1 and S (O )2NRIRdI;
each Cyl is independently C6-10 aryl, C3-10 carbocyclyl, arachadonic acid , elaidic acid , and vaccenic acid .
5-10 membered heteroaryl or 4-10 membered heterocyclyl,
In some embodiments , Z is CO2R “.
each ofwhich is unsubstituted or substituted by 1 , 2 , 3 , 4 or 20

5 substituents independently selected from C1-6 alkyl , C ,
alkenyl, C2-6 alkynyl, halo, CN ,NO2, ORCI, SRal, C (O )RI,
C (O )NRCRdi, C (O )ORT, OC (O )RbI, OC (O )NRCIRDI

CENREINRIR

NRCCSNRI) NRCIRI NRCIRI,

As noted above, any known method of polymerization for

alkenes may be used with the monomers described herein .
For example , in the presence of selected transition metal
catalysts , a monomer as provided herein can undergo

metathesis with other alkenes . In the absence of a thermo

NRC COROT, NR C(O )ORI, NRIC(O )NRCIRI, NR IS 25 dynamic driving force, these exchange reactions typically
(O )R51, NRCIS(O ), Rb1, NRCIS (O ) NRC?R (I, S (O )R51, S (0 ) producemixtures of the starting and product alkenes. For the

NRCIR'l, s (o ) R67; s(0 )2NR Rd and oxo ;

monomers provided herein , however, the metathesis reac
each Ral, Rbi, Rei, Rd1, is independently selected from H , tion is driven forward by relief of strain to result in rapid and
C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 typically irreversible ring -opening metathesis polymeriza
aryl, C3-10 carbocyclyl, 5-10 membered heteroaryl, 4-10 30 tion (ROMP ). As shown in Scheme 2 for a ROMP process
membered heterocyclyl, C6-10 aryl-C1-4 alkyl, C3-10 carbo with a generic cycloalkane.
r

Scheme 2

Un
in

cyclyl-C1-4 alkyl, (5-10 membered heteroaryl)-C1-4 alkyl or
( 4-10 membered heterocyclyl) -C1-4 alkyl, wherein said C1-6
alkyl, C2-6 alkenyl , C2-6 alkynyl, C6-10 aryl, C3-10 carbocy- 45
clyl, 5-10 membered heteroaryl, 4-10 membered heterocy
clyl, C6-10 aryl-C1-4 alkyl, C3-10 carbocyclyl- C1-4 alkyl,
(5-10 membered heteroaryl)-C1-4 alkyl and (4-10 membered
heterocyclyl)-C 1.4 alkyl is optionally substituted with 1, 2 , 3 ,

See , for example , Bielawski, Christopher W .; and Grubbs,
Robert H., Progress in Polymer Science (2007), 32 ( 1), 1-29 .
Publisher : Elsevier Ltd.; Trimmel, Gregor, et al. Advances in
Polymer Science (2005), 176 (Metathesis Polymerization ) ,
43-87 . Publisher: Springer GmbH ; Slugovc , Christian , Mac
romolecular Rapid Communications ( 2004 ), 25 ( 14 ), 1283
1297; Grubbs, Robert H. and Khosravi, Ezat. Materials

4 , or 5 substituents independently selected from C4-4 alkyl, 50 Science and Technology (1999), 20 (Synthesis ofPolymers),
C14 haloalkyl, halo, CN , OR04, SR44, C (O )Rb4, C (O )
Publisher: Wiley -VCH ; Buchmeiser, Michael R.
NR 4R04, C (O )ORC4, OC (O )R54, OC (O )NR *R44,NR 4R04, 65-104
Chemical Reviews (Washington , D.C.) (2000 ), 100( 4 ),

NRC4C (O )Rb4, NRC4C (O )NRC4R04, NR 4C (O )ORC4 1565-1604; Madan , Rajni, et al., Progress in Polymer Sci
CNR 4)NRC4R14, NROCENR4) NR 4R44, S ( O ) Rb4, ence ( 1998 ), 23 (4 ), 621-663.
S ( O )NRC4R04, S (O )2Rb4, NRCAS (O ) 2Rb4, NRC +S (0 )2 55 With a monomer as provided herein , an example reaction
2

NR 4Rd4 and S (O )2NRC4Rd4;

each Ra4, R64,RC4 and Rd4 is independently selected from

is as shown in Scheme 3 .

H , C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl and C2-4 alkynyl,
wherein said C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl, is
optionally substituted with 1, 2, or 3 substituents indepen- 60
dently selected from OH , CN , amino , halo , C -4 alkyl, C1-4
alkoxy, C1-4 alkylthio ,C1-4 alkylamino , di(C1-4 alkyl)amino ,
C -4 haloalkyl, and C.4 haloalkoxy .
In some embodiments, the substituents can be selected
from the group consisting of an alkyl , a halogen , a hydroxyl, 65 C3H17
an alkoxyl, a carbonyl ( such as a carboxyl, an alkoxycar
bonyl, a formyl, or an acyl), a thiocarbonyl (such as a

Scheme 3

PCy3
Cl

H

Ru

CI
OH

Grubbs'

|

Ph
???? Fh_1
(1 mol % )

THF , ethylvinyl ether
61 %
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-continued

-continued

o

CI.

COOH

C8H17
tacky dark -purple

H

Grubbs'

ci ????
|

Ph 1st (5 mol % )
CH2Cl2 , ethylvinyl ether

5

solid

In some embodiments , one or more monomers as pro
vided herein can be reacted with other alkenes , either

????

Ru

10

monomeric alkenes or alkene- containing polymers, through

cross metathesis (CM ) wherein two alkenes can undergo

transalkylidenation under release of ethane in the presence
of a ruthenium carbenoid (e.g., Grubbs ' Catalyst). In the

15

absence of a thermodynamic driving force, these exchange
COOH
68 %
reactions typically produce mixtures of the starting and
C8H17
product alkenes . For the cyclobutene -containing monomers
provided herein , however, the cross metathesis reaction is
driven forward by relief of strain . Two exemplary reactions 20 For example , a polymer can be prepared as follows.
with monomeric alkenes are shown in Scheme 4 .
Under an inert atmosphere , a solution of catalyst (Grubbs' I
or II) in THF was added to a vigorously stirred solution of
0.2 M monomer in THF. The reaction mixture is then stirred

Scheme 4

C2H17

OH

25

+

????

H

30

Ru

c |

????

OBn

Grubbs'

Ph 1st (5 mol % )

CH2Cl2

for about 30 min at room temperature after which the
reaction is terminated by addition of a small amount of ethyl
vinyl ether. The mixture is allowed to stir at room tempera

ture for 30 min . and poured into methanol to precipitate the
the solutions dried with typical agents (magnesium sulfate ,
sodium sulfate) before further purification reprecipitation
using dry methanol (2x). The polymer can be analyzed by

polymer. The polymer is then resolubilized in dry THF and

gel permeation chromatography (GPC ) in THF or by proton
35 'H NMR as a solution in CDC1z.
In some embodiments, radical polymerization methods
may be used to prepare a polymer as provided herein . Free

OBn

radical polymerization is a method of polymerization by

COOH

73 %

40

C8H17
45

C2H17

OH

+

which a polymer forms by the successive addition of free
radical building blocks. Free radicals can be formed via a

number of differentmechanisms usually involving separate
initiator molecules . Following its generation , the initiating
free radical adds (nonradical) monomer units , thereby grow
ing the polymer chain . Any reasonable initiator may be used
in these polymerization reactions. An example of such a
reaction is shown in Scheme 5 .
Scheme 5

initiator

ONa

COON
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In some embodiments , the diene can be a substituted

useful in bioorthogonal " click " chemistries. Bioorthogonal tetrazine or other heteroaromatic ring system with at least
reactions for coupling materials in the presence of complex two nitrogens adjacent to each other and which is a highly
biological milieu are of great interest in biology and medi reactive participant in the inverse electron demand Diels
cine . Such reactions have become key components in a 5 Alder reaction . The diene is linked to the payload (which can
variety of applications including protein engineering, immu be, e.g., a therapeutic agent, fluorescence dye , or other
noassay development, and cell surface modification . (Link J detectable agent). In these embodiments, the diene possesses
A et al., 2003 , Curr Opin Biotechnol 14 :603-609 ; Wang
a reactive group such as an amine, alcohol, carboxylic acid
et al., 2003 , J Am Chem Soc 12 :3192-3193 ; Dimandis E P et or
ester, or other group that can undergo a chemical reaction

al., 1991, Clin Chem 37:625-636; Baskin J M et al., 2007, 10 with the reactive moiety on the payload to form a link

Proc Natl Acad Sc. USA 104 : 16793-16797; Link J A et al.,

2003 , J Am Chem Soc 125 :11164-11165 ). Presently , a few
types of bioorthogonal reactions have been reported , the

most popular being the Staudinger ligation and the [3 + 2 ]

between the two .
Dienes

Dienes useful in the present disclosure include but are not

cycloaddition “ click ” reaction between azides and alkynes. 15 limited to aromatic ring systems that contain two adjacent
( Prescher J A et al., 2004, Nature 430 ( 7002 ):873-877 ; nitrogen atoms, for example, tetrazines , pyridazines, substi
Rostovtsev V V et al., 2002, Angew Chem Int Ed 41 ( 14 ):

tuted or unsubstituted 1,2 -diazines. Other 1,2 -diazines can
1,2 - diazines annelated to a second n -electron -defi
Bioorthogonal “ click ” chemistries are widely used in include
cient
aromatic
ring such as pyrido [3,4 -d ]pyridazines ,
chemical biology for a myriad of applications such as 20
[4,5 -d ]pyridazines, and
1,2,4 -triazines .
activity based protein profiling , crosslinking of proteins, pyridazino
Pyridazines
can
also
be
fused
with
a
five
membered
hetero
monitoring cell proliferation , generation of novel enzyme cycle such as imidazo [4,5 - d ]pyridazines and 1,2,3-triazolo
inhibitors, monitoring the synthesis of newly formed pro
teins, protein target identification , and studying glycan pro [4,5 -d ]pyridazines. In some preferred embodiments, the
cessing. Perhaps the most fascinating applications involve 25 diene is an asymmetrical tetrazine as described herein , e.g.,
using these bioorthogonal chemistries to assemble mol 3-(p -Benzylamino )-1,2,4,5 -tetrazine:
ecules in the presence of living systems such as live cells or
even whole organisms (Baskin et al., 2007, Proc Natl Acad
H2N
Sci USA , 104 , 16793-7 ; Laughlin et al., 2008 , Science, 320 ,
664-7 ; Prescher and Bertozzi, 2005 , Nat Chem Biol, 1 , 30
13-21 ; Neef and Schultz, 2009 , Angew Chem Int Ed Engl,
2596-2599 ).

48 , 1498-500 ; Ning et al., 2008 , Angewandte Chemie
International Edition , 47 , 2253-2255 ). These latter applica

tions require that the chemistry be non - toxic and possess

kinetics that allow fast reaction to occur with micromolar 35

concentrations of reagents in a time span of minutes to
N
hours .
Bioconjugation methods using inverse electron demand
N.
Diels - Alder cycloadditions between tetrazines and highly
strained dienophiles such as norbomene and trans -cy- 40
clooctene are known in the literature , however the tetrazine
used has limited stability to aqueous media . ( Blackman et
Two non -limiting examples of such a “ click ” chemistry
al., 2008 , J Am Chem Soc , 130 , 13518-9 ; Devaraj et al., reaction is show in Scheme 6 .
2009, Angew Chem Int Ed Engl, 48 , 7013-6 ; Devaraj et al.,
2008 , Bioconjug Chem , 19 , 2297-9 ; Pipkom et al., 2009 , J 45
Pept Sci, 15 , 235-41). To improve upon the stability of the
Scheme 6
tetrazine, a novel asymmetric tetrazine was employed that
NEN
=

demonstrated superior stability in water and serum and can
react with trans-cyclooctene at rates of approximately 103
M- sec -1 at 37 ° C. ( Devaraj et al., 2009, Angew Chem Int 50
Ed Engl, 48, 7013-6 ). This extremely fast rate constant

allows for the labeling of extracellular targets at low nano
tions that are sufficiently low to allow for real- time imaging
55
of probe accummulation .
In some embodiments, the ligand, e.g., an antibody , small
molecule or other biomolecule , can be physically attached to
the dienophile. In some embodiments, the ligand carries a
functional group such as an amine, alcohol, carboxylic acid
or ester, or other group of atoms on the ligand that can 60

molar concentrations of tetrazine labeling agent, concentra

undergo a chemical reaction allowing attachment to the
dienophile . Alternatively or in addition , the dienophile or
heterodienophile (e.g. , a cyclobutene compound as provided
herein ) possesses a reactive functional group for attachment

to the ligand (e.g., Z ). Thus, the reactive functional group on 65
the ligand and /or dienophile undergoes a chemical reaction

to form a link between the two .

N -

N

3,6 -di(2 -pyridyl)-tetrazine

C3H17

THF

OH

N
OH

C8H17
About 75 % conversion

With 53 % yield
1 hr. 30 min .
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-continued

N - N

N

5

COOH

c

NEN

N

carbon double bonds which provide the cross-linking ele
ment can be cross-linked by the samemethods used for latex
of butadiene rubbers, allowing the incorporation of a two
dimensional crosslink within a coating or layer.

The polymers provided herein can form two-dimensional

or three -dimensional ordered polymers or coatings . For

example , see Scheme 7 .

C3H17

10

Scheme 7

N

ROMP

THF
88 %

3,6 - di( 2-pyridyl)-tetrazine

polymerization
CO2H

15 Monomer

C2H17

in ordered
medium

OH

N - N

N

mena

ROMP

polymerization

20

in solution

(no 2D order)

COOH

C3H17

primo

Accordingly, provided herein is an amphiphilic polymer 25
formed by polymerizing a compound as provided herein
( e.g., a compound of Formula (IV ) or an amphiphilic

cycloalkene -containing fatty acid derivative ), each having a
hydrophobic end, a hydrophilic end , and a backbone there
between comprising a cycloalkene, wherein the cycloalkene 30
comprises at least four carbon atoms, with at least two of the

podno

four carbon atoms being part of the backbone of the amphi

philic cycloalkene-containing fatty acid derivatives.In some
embodiments, the polymer comprises amphiphilic fatty acid

derivatives cross -linked via an unsaturated hydrocarbon 35
chain formed by cleavage of the cycloalkene. In some
embodiments , the polymer is ordered in two or three dimen
sions.
Further provided herein is a polymer comprising a repeat
ing unit having the structure

pun
porno

40

== C - CR !_CR - C = ) = ,
where :

empurn

Rl is hydrophobic and comprises a substituted or unsubsti

tuted alkyl group having at least one carbon atom or a 45
substituted or unsubstituted alkenyl group having at least
two carbon atoms, and

R² is hydrophilic and comprises a substituted alkyl group

having at least one carbon atom or a substituted alkenyl
50
group having at least two carbon atoms.
In some embodiments, the substituted alkyl group or
substituted alkenyl group of R2 comprises a hydroxyl group ,

Examples of applications of such polymers or coatings
1 ) Polymerization of monolayer or multilayer films
derived from Langmuir -Blodgett techniques (either
directly on a Langmuir trough or after transfer of a
monolayer or multi layers to a substrate by dipping).
2 ) Polymerization of monolayer or multilayer films

include :

an ester group , an aldehyde group , a carboxyl group , a
sulfhydryl group , an amine group , an amide group , a carb
55
amide group , or a phosphate group .
derived from polar interactionsbetween the amphiphile
The polymers provided herein may be used in a number
and inorganic or organometallic colloids such as quan
of applications. For example, the polymers may undergo
tum dots .
further manipulation such as cleavage, stabilization , and/or
3 ) Polymerization within micelles , bilayers, liquid crys
cross- linking. For example, the carbon -carbon double bonds
introduced through certain polymerization reactions (e.g., 60
tals , and liposomes . These aggregates may be com
posed solely of the amphiphilic cyclobutenes or else
ROMP polymerization ) can be cleaved by oxone or a similar
mixtures of the amphiphilic cyclobutenes with other
oxidant, thus providing a means of breaking the polymer
amphiphilic components.
back to monomeric components . In some cases, the carbon
4 ) Polymerization ofmonolayer or multilayer films of the
carbon double bonds which provide the cross- linking ele
amphiphilic cyclobutenes onto a chromatographic sup
ment can be saturated (hydrogenated ) to form highly stable 65
alkane linkages, making the polymer much less susceptible
port such as silica to create a remarkably stable reverse
to oxidative cleavage. In some embodiments, the carbon

phase chromatographic layer capable of displaying any
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desired functional group that can be incorporated into
commercial reverse phase chromatography columns
are prepared by chemical bonding of C8 or C18 alkyl
silanes to a silica surface via siloxane bonds. The 5
resulting siloxanes are only stable within a fairly mod
est pH range . If a reverse -phase chromatography col
umn was instead prepared using a cyclobutene -substi
tuted monomer (for example , with a terminal siloxane
grafted onto or in place of the carboxylic acid ), treat
ment with a ROMP catalyst could provide a new 10
chromatographic support maintaining the same funda
mental features of existing supports yet possessing far
greater hydrolytic stability.
5 ) The ability to prepare cyclobutenes having a close 15
structural analogy to natural fatty acids, combined with
the facility of achieving cross-metathesis of the
cyclobutenes with other alkenes, will enable the use of
the cyclobutene fatty acid as a means of stabilizing or
solubilizing proteins or chemical reagents within bio 20
logical membranes. A targeted protein or agent would
the cyclobutene precursors. By way of comparison ,

The reactions for preparing the compounds provided

herein can be carried out in suitable solvents which can be

readily selected by one of skill in the artof organic synthesis.
Suitable solvents can be substantially non -reactive with the

starting materials (reactants), the intermediates, or products

at the temperatures at which the reactions are carried out,
e.g., temperatures which can range from the solvent's freez
ing temperature to the solvent's boiling temperature. A given
reaction can be carried out in one solvent or a mixture of

more than one solvent. Depending on the particular reaction
step , suitable solvents for a particular reaction step can be
selected by the skilled artisan .

be functionalized with one ormore alkene units in the
form of allyl ethers , allyl esters, or allyl amides ) and

Preparation of the compounds provided herein can
involve the protection and deprotection of various chemical
groups . The need for protection and deprotection , and the
selection of appropriate protecting groups , can be readily
determined by one skilled in the art . The chemistry of
protecting groups can be found , for example , in Protecting
Group Chemistry, 1st Ed ., Oxford University Press , 2000 ;
March's Advanced Organic Chemistry: Reactions, Mecha

after absorption within the skin , hair, or nail, would
result in a new class of remarkably durable cosmetic

magnetic resonance spectroscopy (e.g., 'H or 13C ), infrared

then subjected with cross -metathesis with a nisms, and Structure, 5th Ed., Wiley - Interscience Publica
cyclobutene fatty acid to create a protein “ decorated ” 25 tion , 2001 ; and Peturssion , S. et al., " Protecting Groups in
with fatty acids, fatty acid esters, phospholipids, or Carbohydrate Chemistry," J Chem . Educ., 74 (11), 1297
triglycerides.
(1997 ).
6 ) Polymerization or cross-metathesis of cyclobutene
Reactions can be monitored according to any suitable
containing fatty acids, or their conjugates with proteins, 30 method known in the art. For example, product formation

can be monitored by spectroscopic means, such as nuclear
and therapeutic agents. The ability to polymerize the spectroscopy, spectrophotometry (e.g., UV -visible ), mass
absorbed fatty acid under conditions that selectively spectrometry, or by chromatographic methods such as high
target the cyclobutene would create strong and biomi performance liquid chromatography (HPLC ), liquid chro
metic coatings, with potential applications for cosmet- 35 matography -mass spectroscopy (LCMS), or thin layer chro
ics, skin protective or tanning agents , hair thickeners, matography (TLC ). Compounds can be purified by those
and wound coatings .
skilled in the art by a variety of methods , including high
performance liquid chromatography (HPLC ) (“ Preparative
Synthesis
LC -MS Purification : Improved Compound Specific Method
40

The compounds provided herein , including salts thereof,
can be prepared using known organic synthesis techniques
and can be synthesized according to any of numerous
possible synthetic routes .

Optimization ” K. F. Blom , et al., J. Combi. Chem . 6 (6 ), 874
(2004 ) and normal phase silica chromatography .
In some embodiments, the compounds provided herein
can be prepared as described in the Examples provided

herein and as illustrated in Scheme 8 :
Scheme 8

othershme
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R

OH
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( 3 ) R = C8H17
( 10 ) R = H

g

OBn

??,

HO

h

OA5 , DA5

R

OH

7

OH

R

OA6 , DA6

(4 ) R = C3H17
(11) R = H

XL - XL

OBn

OAZ

5

a ) DMAP, DCC, BOH , 85 % (OA1), 99 % (DAI); b1 ) Zn dust (5 equiv ), Cl3CCOCI
(2.5 equiv ) rt, ether, 85 % for OA2 and 80 % for DA2; b2 ) Zn(Cu) (5 equiv ), C13CCOCI(2.5
equiv ), rt, ether 63 % ; c ) NaBH4, 2 -propanol, 55 % (OA3), 57 % (DA3); d ) MsC1, Et3N , 92 % (OA4 and
DA4); e) Na/NH3, -78 to -33 ° C., 87 % ( 1), 52 % (8); f) H2, Pd/C ETOAc , 96 % (2), 89% (9 ), 87 % ( 3), 90 %

(10 ), 81 % (4 ), 54 % ( 11 ), 70 % (5 ); g ) Zn (5 equiv ), ACOH 87 % (OA5) and 59 % (DA1); h ) NaBH4,MeOH ,
-10 ° C., 99 % for OA6 and 76 % for DA6; i) Zn, ( 1.1 equiv ), AcOH , 97 % for OA5 and 70 % for EA5.

As shown above , the preparation of cyclobutene com
pounds as provided herein (e.g. , 1) can occur using the

tanol (e.g. , 4 ) analogs can be prepared through a variation of
the above in which the initial dichlorocyclobutanone is
dehalogenated , for example , with excess zinc in acetic acid .

following procedures . The benzyl ester of oleic acid under

goes cycloaddition with dichloroketene to afford a mixture 30 A mixture of regioisomeric monochlorocyclobutanones
of regioisomeric dichlorocyclobutanones, each predomi ( e.g., 5 ) can be prepared by partial reduction of the dichlo

rocyclobutanone with 1.1 equiv of Zn or Zn ( Cu ) in acetic
nantly as the cis stereoisomer . The dichlorocyclobutanones acid
. For the preparation of cyclobutanone, cyclobutanol and
possessed limited stability and are directly reduced with monochlorocyclobutanones
, the final step can include
sodium borohydride to furnish a mixture of regioisomeric removal of the benzyl ester by
-mediated hydrogenolysis .
2,2 -dichloro - 1 -cyclobutanols. Conversion to the corre- 35 Compound having shorter Pdchains
(e.g., 8-11) can be
sponding methanesulfonate (mesylate) esters is followed by prepared analogously from 9-decenoic acid , furnishing com
reaction with sodium in ammonia , resulting in simultaneous parably functionalized substrates with lower log P. The
deprotection of the benzyl ester and fragmentation /reduction trans - stereoisomers of cyclobutenes (e.g., 2 ) and monochlo
of the B -chloromethanesulfonate , generating cyclobutene 1 rocyclobutanones (e.g., 7) can be prepared using a similar
in quantities of up to severalhundred milligrams. Hydroge- 40 route based upon elaidic acid (Scheme 9 ). In some cases,the
nation of the compound can provide the corresponding cycloaddition step can be conducted only in the presence of
cyclobutane ( e.g., 2). A cyclobutanone (e.g., 3 ) and cyclobu

activated Zn or Zn /Cu .

Scheme 9
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OH
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a ) DMAP, DCC ,BOH , 95 % (EA1); b2 ) Zn( Cu ) (5 equiv ), Cl3CCOCI (2.5 equiv ), it,
ether 63 % ; c) NaBH4, 2 -propanol, 85 % (EA3); d ) MsC1, Et3N , 86 % (EA4); e) Na/NH3,

-78 to -33 ° C., 46 % (6 ); f) H2, Pd /C ETOAc, 54 % (7).
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Accordingly, provided herein is a method comprising:

matography was performed on 32-60 um silica gel. Prepara
tive HPLC was performed on a 21x250 mm normal phase Si
(8 micron ) column at 10 mL /min of the indicated solvent
unless otherwise noted . Analytical purity of compounds was
dibromoketene ) to achieve a stereospecific cycloaddition 5 checked using an analytical column (250 mmx4.6 mm ;
across the at least one carbon -carbon double bond , Microsorb ) at 1 mL /min of 20 % EtOAc /Hexane ; detection
thereby yielding a cycloketone-containing fatty acid was accomplished using a differential refractometer inter

reacting an unsaturated fatty acid or derivative thereof
having a backbone comprising at least one carbon -carbon
double bond with dihaloketene (e.g., dichloroketene or

derivative comprising a cycloketone along the backbone , faced with a data module. All compounds tested for bio
wherein the cycloketone comprises at least four carbon logical activity showed > 97 % purity by HPLC analysis
atoms, with at least two of the at least four carbon atoms 10 except for 5 and 7. Melting points are uncorrected . Mass
being part of the backbone of the cycloketone-containing spectral analyses were carried out by HRFAB on 3 -nitroben
fatty acid derivative ;
zyl alcohol (3 -NBA ) or glycerol matrices at the Nebraska
reducing the cycloketone-containing fatty acid derivative to Center for Mass Spectrometry .
yield an amphiphilic cycloalkene -containing fatty acid
Example 1 Preparation of Compounds
derivative having a hydrophobic end , a hydrophilic end , 15
and a backbone therebetween comprising a cycloalkene,
wherein the cycloalkene comprises at least four carbon
( Z )-9 -Octadecenoate , benzyl ester (benzyl oleate , OA1)
atoms, with at least two of the four carbon atoms being was prepared by a variation of a known procedure (Ravigli
part of the backbone of the amphiphilic cycloalkene one , M. et al. Lancet 2012 , 379 : 1902-1913 ). Benzyl alcohol
20 (3.83 g, 35.4 mmol) was added to a stirred solution of oleic
containing fatty acid derivative .
In some embodiments , the method further comprises acid (5.136 g , 18.1mmol) and DMAP ( 43.7 mg, 3.57 mmol)
polymerizing a multiplicity of the amphiphilic cycloalkene
in CH C12 (40 mL). The solution was cooled to 0 ° C. and
containing fatty acid derivatives to yield a polymer com
DCC (4.211 g , 20.4 mmol) was added . The mixture was
prising carbon -carbon double bonds. In some such embodi allowed to warm to room temperature and was stirred for 2.5
ments
, polymerization can include cross-linking the 25 hours. The resulting suspension was filtered through a cotton
amphiphilic cycloalkene-containing fatty acid derivatives plug and the precipitate was washed with CH C12. The
via the carbon- carbon double bond in the cycloalkene. In CH ,C1, solution was washed with water and dried over

some embodiments, polymerizing the multiplicity of the
amphiphilic cycloalkene - containing fatty acid derivatives

Na2SO4. Evaporation of the organic solvent and flash chro
matography of the residue over silica gel, using 5 % EtOAc /
comprises ring-opening metathesis reactions. In some 30 Hex , gave benzyl oleate OA1 (5.73 g, 85 % ) as a colorless
embodiments, polymerizing the multiplicity of the amphi oil : R = 0.83 (10 % EtoAc/Hex ); IR ( ZnSe, cm - l) 2924 ,
philic cycloalkane-containing fatty acid derivatives com
2853 , 1738 , 1456 , 1162 , 696 cm-?; ' H NMR : 8 7.38-7.31

prises click -chemistry . For example, the amphiphilic ( 5H ), 5.41-5.31 ( 2H ), 5.13 (s, 2H ), 2.37 (t, J = 7.6 Hz, 2H ),
cycloalkane -containing fatty acid derivative can be reacted 2.05-2.00 (4H ), 1.70-1.62 (m , 2H ), 1.40-1.29 ( 20H ), 0.90 (t,
with a substituted or unsubstituted tetrazine.
35 J= 6.8 Hz, 3H ); 13C NMR 8 173.6 , 136.12 , 129.9 , 129.7 ,
In some embodiments, the method further comprises 128.5 (two overlapping signals ), 128.11, 128.09, 66.0 , 34.3 ,
hydrogenating the carbon -carbon double bonds of the poly
31.9, 29.7 , 29.6 , 29.50 , 29.3 , 29.1 , 29.1, 27.2 , 27.1, 24.9 ,
mer. In some embodiments , the method further comprises 22.7 , 14.1 .
cleaving at least some of the carbon -carbon double bonds in
2,2 -Dichloro -4 - octanoic acid benzyl ester , 8 -yl) 3 -octyl
the polymer via oxidation to yield monomeric products. 40 cyclobutanone-; 2,2 -Dichloro -3-(octanoic acid benzyl ester ,
The backbones of the multiplicity of the amphiphilic 8 -yl) 4 -octylcyclobutanone (OA2); was prepared by a modi
cycloalkene-containing fatty acid derivatives can be aligned fication of a known procedure (Raviglione, M. et al. Lancet
before polymerizing the multiplicity of the amphiphilic 2012 , 379 : 1902-1913 ). To a mixture of zinc dust (0.879 g ,
cycloalkene-containing fatty acid derivatives .
13.4 mmol) and benzyl oleate OA1 ( 1.019 g , 2.73 mmol) in
45 20 mL of anhydrous ether was slowly added a solution of
EXAMPLES
trichloroacetyl chloride (0.75 mL , 6.8 mmol) in 7 mL of
diethyl ether via dropping funnel over a period of 45 min .
The invention is further described in the following The reaction was stirred until judged complete by the
examples, which do not limit the scope of the invention absence of starting material (4 h , TLC ). The reaction mixture
described in the claims.
50 was filtered through a plug of Celite and the residue was
General Procedures
washed with ether (2x75 mL ). The organic solution was
All reagents and solvents were used as purchased except stirred a minimum with 50 % aq. NaHCO3 and the separated

for pyridine and CH C12 (distilled from CaH , and kept under aqueous layer back -extracted with ether (2x20 mL ). The
N2) and THF (distilled from Na/benzophenone under N2). combined organic layers were dried over Na2SO4 and con
Thin -layer chromatography ( TLC ) was performed on 0.25 55 centrated under vacuum to give 1.3041 g of the product
mm hard - layer silica G plates ; developed plates were visu
( 99 % ) as a yellow oil. The unpurified material was generally
alized with a hand-held UV lamp or by staining: 1 % used directly for the next reaction because of a tendency to
Ce (SO4) 2 and 10 % (NH4)2M004 in 10 % aq . H2SO4 (general decompose during chromatography. However, small quan
stain , after heating); 1 % aq . KMnO4 ( for unsaturated com
tities could be purified by rapid flash chromatography (5 %

pounds); 3 % vanillin in 3 % H2SO4 in EtOH (general stain , 60 EtoAc/Hex ) to afford a 1: 1 mixture of regioisomeric dichlo
after heating). Unless otherwise noted , NMR (spectra were rocyclobutanones OA2 as a colorless oil: R , 0.53 ( 10 %
recorded at 400 MHz (' H ) or 100 MHz (13C ) in CDC13 ; EtOAc/Hex ); IR (ZnSe, cm -1) 2926 , 2855 , 1800 , 1735 ,

peaks are reported as: chemical shift (multiplicity, J cou
1456 , 1162, 696 cm -l; ' H NMR : d 7.36-7.32 (5H ), 5.120 /
plings in Hz, number of protons); " app ” and “ br” refer to 5.116 (overlapping s, 2H ), 3.55-3.49 (m , 1H ) 2.97-2.93 (m ,
apparent and broad signals , respectively . IR spectra were 65 1H ), 2.37/2.35 (overlapping t, J = 7.6 Hz, 2H ), 1.74-1.62 (m ,
recorded as neat films (ZnSe, ATR mode ) with selected 4H ), 1.66-1.48 (m , 4H ), 1.45-1.27 (br m , 18H ), 0.89 /0.88
absorbances reported in wavenumbers (cm-?). Flash chro
(overlapping triplets , J = 6.9 Hz, total3H ); 13C NMR 8 197.5 ,
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173.5 , 136.1, 128.5 , 128.1 , 88.1, 66.0 , 58.0 , 57.9 , 49.4 , 49.4 ,
Second -eluting cis: R = 0.20 ; IR (ZnSe, cm ') 3464, 2924 ,
34.2 , 31.8 , 31.80 , 29.60 , 29.3 , 29.3 , 29.2 , 29.18 , 29.15 , 2854, 1736 , 1456 , 1169 , 696 cm-'; ' H NMR : 8 7.37-7.32
29.12 , 29.0 , 28.9, 28.9 , 28.04 , 27.96 , 26.72 , 26.68, 26.3 ; (m , 5H ), 5.11 (s, 2H ), 4.55 (dd , J= 10.8 , 8.8 Hz, 1HCH - OH ,
HRFAB -MS (3 -NBA + Limatrix ): calcd . for C27H4003C12Li cis to the backbone assigned based on 2D -NOESY analysis
5 and 43diagonal 1-0 ), 2.72 (dt, J= 9.2 , 5.6 Hz , 1H ), 2.65 (d ,
[ M + Li]* :489.2515 . Found : 489.2499.
2,2 -Dichloro -4-( octanoic acid benzyl ester, 8 -yl) 3 - octyl
J = 10.8 Hz, 1H , OH ), 2.54 (app dq, v= 9.2, 5.6 Hz, 1H ) ,
cyclobutanol-; 2,2 -Dichloro - 3-(octanoic acid benzyl ester, 2.35 (t, J= 7.2 Hz, 2H ), 1.68-1.60 (bm , 3H ), 1.52-1.13 (m ,

8 -yl) 4 -octylcyclobutanol (OA3). Reduction of the dichlo
24H ), 0.89 (app t, J = 6.8 Hz, 3H ); 13C NMR 8 173.7 , 136.1 ,
rocylobutanone OA2 was achieved using a known procedure 128.5 ( two overlapping signals), 128.2 (two overlapping
(Raviglione , M.et al. Lancet 2012 , 379 : 1902-1913 ). To a 0 ° 10 signals), 93.5, 77.2 , 66.1, 49.5, 40.9, 34.3 , 31.8 , 29.6 , 29.4 ,
C. solution of the mixture ofregioisomeric dichlorocyclobu
29.2 , 29.1 , 29.04 , 29.00, 27.0 , 25.8 , 24.8 , 23.2 , 22.7 , 14.1 ;
tanones OA2 ( 1.5 g, 3.1 mmol) in iPrOH (45 mL ) was added HRFAB -MS ( 3 -NBA matrix ): calcd . for C27H4303C12:
NaBH4 (0.176 g , 4.65 mmol). The reaction was allowed to 485.2589 [M + H ]*. Found : 485.2581 .
slowly warm to rt and stirred only until the starting material
Second -eluting trans: R = 0.15 ; IR (ZnSe, cm- ) 3464 ,
had disappeared ( TLC, -2.5 h ; byproducts tended to accu- 15 3033, 2925 , 2854 , 1738 , 1498 , 1160,697 cml; ' H NMR : 8
mulate upon prolonged reaction ). The reaction was then 7.37-7.32 (m , 5H ), 5.11 (s, 2H ), 3.99 ( ddd, J= 10.0 , 8.4 , 1.2
cooled to 0 ° C. and quenched with 1N HCl (40 ml). The Hz, 1H , CH OH , trans to the backbone assigned based on
solution was stirred for an additional 30 min and then
extracted with EtOAC (3x100 mL ). The organic layer was

2D - NOESY analysis and 41',diagonal H = 1.2 Hz), 2.69-2.64 (m ,
1H ), 2.56 (d , J= 10.0 Hz, 1H , OH ), 2.35 (t, J= 7.6 Hz, 2H ),

washed sequentially with water/sat .NaHCO3/brine and then 20 2.26-2.22 (m , 1H ), 1.66-1.26 (m , 27H ), 0.88 (app t, J= 6.8
dried over Na S04. Evaporation of the organic solvent and Hz, 3H ); 13C NMR 8 173.7 , 136.1 , 128.5 ( two overlapping
flash chromatography of the residue on silica gel, using a signals ), 128.2 ( two overlapping signals ), 91.1, 82.6 , 66.1,
step gradient of 5 % / 10 % EtOAc/Hex , gave 0.8212 g (55 %
50.3 , 44.3 , 34.3 , 31.8 , 29.7 , 29.4 , 29.2 , 29.04 , 28.97 , 28.5 ,
yield ) of a 1: 1 mixture of regioisomeric cyclobutanols S2 as 28.21 , 28.18 , 27.5 , 24.8 , 22.7 , 14.1 ; ESI-MS: calcd . for
a colorless oil . The products were predominantly a regioi- 25 C27H4203C12Na: [M +Na] 507.2409. Found : 507.2426 .
someric mixture of the cis , cis diastereomers based on ' H
2,2 -Dichloro -4-( octanoic acid benzyl ester , 8 -yl) 3 -octyl

NMR , HSQC , 2D - COSY and 2D - NOESY analysis: R (10 %
cyclobutanol, methanesulfonate ester; 2,2 -Dichloro - 3-( oc
EtOAc/Hex )= 0.33 (major, OH is cis to backbone ) 0.28 tanoic acid benzyl ester, 8-yl) 4 -octylcyclobutanol, meth
(minor, OH is trans to backbone ), 0.2 (major, OH is cis to anesulfonate ester (OA4) was prepared by a variant of
backbone) and 0.15 (minor, OH is trans to backbone ); IR 30 published procedures (see Baldwin, J. D.and Belfield , K.D.
( ZnSe , cm- ) 3473 , 3036 , 2924 , 2854, 1733 , 1456 , 1168 , J. Org . Chem . 1987 , 52, 4772-4776 ; and Powers , D.C. et al.
696 cm - 7; ' H NMR: 8 7.36-7.32 (m , 5H ), 5.116 /5.112 (app J. Org. Chem . 2007, 72 , 187-194 ):Methanesulfonyl chloride
s , total 2H ), 4.55 (dd , J = 10.8 , 8.8 Hz, 0 . CH - OH , cis (62 ul, 0.80 mmol) was slowly added to a stirred 0 ° C.
to the backbone assigned based on 2D -NOESY analysis and solution of a regioisomeric mixture of cyclobutanols OA3
4Jdiagonal 1 +0), 3.99 (br t, J = 10 Hz, 0.08H ), 2.75-2.69 (m , 35 (0.193 g , 0.398 mmol) and triethylamine (0.25 mL , 8 mmol)
1H ), 2.64/ 2.62 ( overlapping d , J= 10.8 Hz, total 1H , -H in CH2Cl2 (2 mL ) over 15 min . The reaction was allowed to
proton assigned based on the disappearance of this peak slowly warm to rt and was stirred for 17 h or until no starting
upon D20 addition ), 2.60-2.55 (m , 1H ), 2.36 / 2.35 (overlap material remained ( TLC ). The reaction was diluted with 75
ping t, J = 7.6 Hz, total 2H ), 1.67-1.62 (bm , 3H ), 1.52-1.19 inL ofCH2Cl2 and washed sequentially with 1N HCI (2x25
( 24H ), 0.89 /0.88 (overlapping t, J = 6.8 Hz, total 3H ). Small 40 mL ), sat aq .NaHCO3 (2x25 mL ) and water ( 2x25 mL ). The
quantities of the individual isomers could be isolated by organic solution was then dried with Na2SO4 and concen
semipreparative HPLC ( 10 % EtOAc/Hex , RI detection ) :
trated under reduced pressure. The residue was purified by

first -eluting cis: R = 0.33 ; IR (ZnSe, cm-!) 3457, 2924 ,
2854 , 1736 , 1456 , 1170, 697 cm-?; 'H NMR : 8 7.37-7.32

flash chromatography using 10 % EtoAc/Hex to give a light
yellow oil (0.2061 g, 92 % ) consisting of a 1:1 mixture of
(m , 5H ), 5.12 (s, 2H ), 4.55 (dd , J= 10.8 , 8.8 Hz, 1H , 45 regioisomers , each a 92 :8 mixture of cis /trans stereoisomers
CH - OH , cis to the backbone assigned based on based upon ' H NMR : R ( 10 % EtOAc/Hex )= 0.31 ( first
2D -NOESY analysis and 41diagonal 1-0), 2.72 (dt, = 9.2 , 5.6 trans ), 0.26 (first cis/ second trans ), 0.21 (second cis ); IR

Hz, 1H ), 2.59 (d , J = 10.8 Hz, 1H , OH ), 2.55 (app dq ,
J = 9.2 , 5.6 Hz, 1H ), 2.36 (t, J = 7.6 Hz, 2H ), 1.67-1.51 (br m ,
3H ), 1.52-1.13 (m , 24H ), 0.88 (app t, J= 6.8 Hz, 3H ); 13C 50
NMR 8 173.6 , 136.1, 128.5 (two overlapping signals ), 128.2
(two overlapping signals), 93.5 , 77.2 , 66.1, 49.5 , 40.9, 34.3 ,
31.8 , 29.9, 29.4 , 29.4 , 29.3 , 29.2 , 29.0 , 27.0 , 25.7 , 24.9 , 23.2 ,
22.7 , 14.1 ; HRFAB -MS ( 3 -NBA matrix ): calcd . for
55
C27H4303C12 :485.2589 [M + H ]*. Found : 485.2572 .
first -eluting trans: R = 0.28 ; IR (ZnSe, cm ') 3449 , 3028 ,
2920 , 2850 , 1736 , 1456 , 1157, 696 cm-'; ' H NMR : 8
7.37-7.32 (5H ), 5.12 (s, 2H ), 3.99 (ddd , J = 10.0 , 8.4 , 1.2 Hz,
1H , CH OH , trans to the backbone assigned based on

(ZnSe, cm-?) 3032, 2925 , 2855 , 1735 , 1458 , 1180 , 696
cm - 1; 'H NMR : 8 7.36-7.33 (m , 5H ), 5.33 (d, J= 9.6 Hz,
0.92H ), 5.114/5.109 (two s, total 2H ), 4.84 (d , J= 7.6 Hz ,
0.08H ), 3.208 /3.205 ( two s , total 3H ), 2.76-2.74 (m , 2H ),
2.36 / 2.34 (two overlapping t, J= 7.6 Hz, total 2H ), 1.66-1.60
(m , 4H ), 1.46-1.26 (m , 22H ), 0.88/0.87 (overlapping t, J= 6.8
Hz, total 3H ).
Small quantities of individual isomers could be separated
for analysis by HPLC using 10 % EtOAc/Hex . The stereo
chemical assignments were confirmed by 2D -NMR experi
ments and by preparation of individual methanesulfonates
from individual samples ofalchols described in the previous

2D -NOESY analysis and 4Jdiagonal11.2 Hz), 2.68-2.64 (m , 60 step .
1H ), 2.52 (d , J = 10.0 Hz, 1H , OH ), 2.34 (t, J= 7.6 Hz, 1H ),
First eluting trans: R - 0.31; IR (ZnSe, cm -1) 3032, 2926 ,

2.29-2.20 (m , 1H ), 1.67-1.26 (br m , 27H ), 0.88 ( app t, J = 6.8 2855 , 1737, 1733 , 1456 , 1180 , 697 cm '; 'H NMR : 8
Hz, 3H ); 13C NMR 8 173.6 , 136.1 , 128.5 (two overlapping 7.37-7.32 (5H ), 5.12 (s, 2H ), 4.84 (d , J = 7.6 Hz, 1H ), 3.20 (s ,
signals ), 128.2 (two overlapping signals), 91.1, 82.6 , 66.1 , 3H ), 2.74-2.68 (m , 2H ), 2.36 (t, J= 7.6 Hz, 2H ), 1.67-1.32 (br
50.3 , 44.4 , 34.3 , 31.9, 29.7 , 29.5 , 29.2, 29.04, 29.02 , 28.4 , 65 m , 26H ), 0.88 (t, J= 6.8 Hz, 3H ); 13C NMR 8 173.6 , 136.1,
28.23, 28.15 , 27.7 , 24.9 , 22.7 , 14.1 ; ESI-MS: calcd . for 128.5 (two overlapping signals), 128.2 ( two overlapping
C27H4203C12Na: [M +Na] +507.2409. Found: 507.2422.
signals ), 86.4 , 85.8 , 66.1, 50.5 , 41.1, 39.5 , 34.3 , 31.8 , 29.5 ,
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29.4 , 29.3 , 29.2 , 29.01, 28.98, 28.3 , 28.1 , 27.6 , 27.1 , 24.9 , d 180.6 , 140.0 , 139.9 , 46.8 , 46.7 , 34.1 , 31.9 , 29.9 , 29.8 , 29.8 ,
22.6 , 14.1 ; ESI-MS: calcd . for C28H40 ,C1, S : [M +Na ]* 29.7 , 29.6 , 29.5 , 29.3, 29.3 , 29.2 , 29.0 , 28.3 , 28.2 , 24.6 , 22.7 ,
585.2184. Found : 585.2188 .
14.1; HRFAB -MS (Gly matrix ): calcd . for C20H3502
Second -eluting trans: R = 0.26 ; IR (ZnSe, cm ) 3040 , 307.2637. Found [M - H ]": 307.2636 . Purity > 99 % by HPLC
2927 , 2855, 1734, 1456 , 1179 , 697 cm - ; 1H NMR : 8 5 ( retention time, 4.63 min ).
7.37-7.32 (m , 5H ), 5.11 (s, 2H ), 4.84 (dd , J = 8.4 , 0.8 Hz, 1H ),
cis- 9,10 - Ethanooctadecanoic acid (2 ). A solution of
3.19 (s, 3H ), 2.76-2.65 (m , 2H ), 2.35 (t, J = 7.6 Hz, 2H ), cyclobutene 1 (0.031 g , 0.1 mmol) and 10 % Pd /C (0.02 g ,
1.67-1.32 (26H ), 0.89 (t, J= 6.8 Hz, 3H ); 13C NMR & 173.6 , 0.02 mmol) in EtoAc (1 mL ) was placed in a vial under an
136.1, 128.5 ( two overlapping signal), 128.2 (two overlap
atmosphere of H , and stirred at rt overnight (16 h ). The

ping signal), 86.4 , 85.7 , 66.1, 50.5, 41.1, 39.5, 34.3, 31.8 , 10 mixture was then filtered through a plug of Celite and the

29.6 , 29.31, 29.25 , 29.2 , 29.0 , 28.3 , 28.1 , 27.6 , 27.0 , 24.9 ,
22.7 , 14.1 : ESI-MS; calcd . for C28H4403C12S : [M + Na ]*

plug was washed with approximately 10 mL of EtOAc. The
solution was then evaporated under vacuum to afford 0.0297

g of the unprotected acid 2 (96 % ) as a colorless oil which
1736 , 1456 , 1182, 697 cm-?; H NMR : 87.37-7.32 (m , 5H ), 15 (80 :20 : 1 of Hex: EtOAC: ACOH ); IR ( ZnSe, cm ): 3051 (br),

585.2184 . Found : 585.2205 .

First-eluting cis: R ,-0.26; IR (ZnSe, cm ') 2926 , 2855, was pure enough to use without chromatography: R = 0.50

5.33 (app d , J = 9.6 Hz, 1H ), 5.11 (s , 2H ), 3.19 (s , 3H ),
2.80-2.72 (bm , 2H ), 2.36 (app t, J = 7.6 Hz, 2H ), 1.70-1.63

( rn , 4H ), 0.87 (t, J= 6.8 Hz, 3H ); 13C NMR 8 173.6 , 136.0,
128.5 ( two overlapping signal ), 128.1 (two overlapping

2921 , 2852 , 1708 cm - 1; H NMR : 810.93 (br s , 1H , COOH ),
2.35 (t, J = 7.3, 2H ), 2.24 (br s , 2H ), 2.00-1.90 (br m , 1H ),

1.64 ( quintet J= 7.3 , 2H ), 1.60-1.50 (m , 2H ), 1.45-1.10 (br m ,
24H ), 0.88 (br t, J= 7.0 Hz, 3H ); 13C NMR : 8 180.2 , 37.7 ,

signal), 88.9, 80.7 , 66.0 , 49.5 , 40.2 , 39.2 , 34.2 , 31.8 , 29.7 , 20 37.6 , 34.1 , 31.9 , 30.11 , 30.05 , 29.9 , 29.7 , 29.7 , 29.4 , 29.3 ,
29.3 , 29.3 , 29.2 , 29.0 , 28.8 , 26.7 , 25.7, 24.8 , 23.7 , 22.6 , 29.1 , 27.64, 27.55 , 24.8 , 24.7 , 22.7 , 14.1 ; HRCI-MS: calcd .
14.1 : HRFAB -MS ( 3 -NBA matrix ): calcd . for for C20H3802: [M + H ]* 311.2950 . Found : 311.2949 . Purity
100 % by HPLC (retention time, 4.56 min ).
C28H4503C12S : [M + H ]+563.2365. Found : 563.2349 .

Second -eluting cis : R ,-0.21; IR (ZnSe, cm-?) 2925 , 2855 ,
2- (Octanoic acid benzyl ester, 8 -yl) 3 -octylcyclobutanone
1735, 1457, 1181, 697 cm-'; ' H NMR : 8 7.36-7.32 (m , 5H ), 25 and 3-(Octanoic acid benzyl ester, 8 - yl ) 2 -octylcyclobu

5.33 ( app d , J= 9.6 Hz, 1H ), 5.11 (s, 2H ), 3.20 (s, 3H ), tanone (OA5) was prepared by a modification of a known
2.80-2.69 (bm , 2H ), 2.34 (app t, J = 7.6 Hz, 2H ), 1.74-1.60 procedure (see Powers, D.C. et al . J Org. Chem . 2007, 72 ,
(4H ), 1.50-1.19 (22H ); 13C NMR 8 173.6 , 136.1 , 128.5 ( two 187-194 ). To a solution of the regioisomeric dichloroketones
overlapping signal), 128.1 (two overlapping signal), 89.0 , OA2 (0.67 g, 1.4 mmol) in glacial acetic acid ( 3 mL ) was
80.7,66.0 , 49.5 , 40.2 , 39.3 , 34.2 , 31.8 , 29.5 , 29.5 , 29.3 , 29.2, 30 added Zn (Cu) (0.45 g , 6.9 mmol). The mixture was stirred
28.9 , 28.9 , 28.7 , 26.8 , 25.7 , 24.8 , 23.7 , 22.6 , 14.1; HRFAB
at rt under N , until TLC showed complete disappearance of
MS (3 -NBA matrix ): calcd . for C28H450 , C12S : [M + H ]* stating material (~ 5 h ). The reaction mixture was then
563.2365 . Found : 563.2360 .
filtered through a plug of Celite and washed with ether . The
1-(Octanoic acid , 8 - yl)-2 -octylcyclobutene (1 ) was pre
filtrate was washed sequentially with saturated aq. NaHCO3
pared from the unpurified dichloromethanesulfonate using a 35 and water , and dried over Na2SO4. The residue obtained
reported procedure (see Baldwin , J. D. and Belfield , K. D. J upon concentration was purified by flash chromatography on
Org . Chem . 1987 , 52, 4772-4776 ; and Powers, D. C. et al. silica gel (5 % EtoAc in Hex ) to afford 0.388 g (87 % ) of a
J. Org. Chem . 2007 , 72 , 187-194 ). NH3 (~ 15 mL , liquid ) mixture ofregioisomeric cyclobutanones OA5 as a colorless

was condensed into a 100 -mL three -necked round bottom
flask fitted with a dry ice /acetone condenser. Sodium (0.1127 40
g , 4.90 mmol, sliced under Hex ) was added in small pieces.
The resulting deep blue solution was stirred for 20 min . A
solution of 0.2761 g (0.49 mmol) of the mixture of regioi
someric methanesulfonates S3 in anhydrous THF ( 1.5 mL )
was added over 10 min . The reaction was removed from the 45
dry ice bath and allowed to stir at -35 ° C. ( refluxing NH3)
5-30 min (depending on the scale of preparation ). The
reaction was then recooled to -78 ° C. (dry ice /acetone ) and
stirred for 2 h or until the starting material was consumed by
TLC . Saturated aq . NH4Cl was slowly added until the blue 50

color was no longer visible . The condenser was removed and
the reaction mixture was slowly allowed to warm to 0 ° C.
with evaporation of NHz. The remaining reaction mixture
was diluted with 30 mL of water and the suspension was
extracted with CH2Cl2 ( 3x50 mL ). The organic layers were 55
combined and washed sequentially with 1N aq . HCl/water/
saturated aq . NaHCO3/water/brine . The organic solution
was then dried with NaSO4, and concentrated under reduced
pressure. The residue was purified by flash column chroma
tography using 10 % EtOAc/Hex to afford the cyclobutene 60
carboxylic acid (0.1312 g, 87 % ) as a low -melting white
solid : R20.50 (80 : 20 : 1 of Hex : EtOAc: ACOH ); mp = 33-35°
C .; IR (ZnSe , cm-?) 3493 , 3036 , 2923 , 2853, 1708 , 1467 ,
1275 , 728 cm '; ' H NMR : 8 10.94 (br s, 1H , COOH ),
6.17-6.15 (br m , 2H ), 2.83-2.75 (br s , 2H ), 2.35 (t, J= 7.6 Hz, 65
2H ), 1.68-1.60 (br m , 2H ), 1.52-1.40 (br m , 2H ), 1.35-1.20
(23H ), 0.88 (t, J = 6.8 Hz, 3H ); 13C NMR (found 18 carbons)

oil: R = 0.41 ( 10 % EtOAc/Hex ); IR (ZnSe, cm ') 3034 ,
2923 , 2853 , 1774 , 1735 , 1161, 696 cm - 1; H NMR : 8
7.36-7.26 (br m , 5H ), 5.115 (s, 2H ), 3.28-3.17 (br m , 1H ),
3.15-3.05 (br m , 1H ), 2.51-2.43 (m , 1H ), 2.42-2.32 (br m ,
1H ), 2.35 /2.34 (overlapping t, J = 7.53 Hz, 2H ), 1.70-1.50 (br
m , 4H ), 1.45-1.14 (br m , 22H ), 0.88 /0.87 (overlapping t,
J = 7.19 Hz, 3H ); 13C NMR 8 212.0 , 173.6 , 136.1, 128.5 ,
128.1, 66.0 (br s ), 61.9761.8 (two app s ), 50.1 /50.1 (two app

s ), 34.2 , 31.8 , 30.1 , 30.0 , 29.6 , 29.6 , 29.5 , 29.4 , 29.4 , 29.23,
29.17 , 29.0 , 28.2 , 28.08 , 28.05 , 27.98 , 27.6 , 24.9 , 24.3 , 24.3 ,
22.6 , 14.1 ; HREI-MS : calcd . for C27H4,03Na, 437.3032.
Found [M + Na]*: 437.3029.

2-(Octanoic acid , 8 -yl) 3 -octylcyclobutanone and 3-(oc
tanoic acid , 8 -yl) 2 -octylcyclobutanone (3 ). A solution of the
cyclobutanone OA5 (0.0391 g, 0.09 mmol) and 10 % Pd /C
(0.020 g, 0.18 mmol) in anhydrous MeOH ( 1 mL ) in a vial
was placed under an atmosphere of H , and stirred at rt
overnight (16 h ). The mixture was then concentrated under
vacuum . The residue was resuspended in EtOAC (~ 20 mL )
and filtered through a plug of Celite. The residue obtained
upon concentration was purified by flash column chroma

tography on silica gel (10 % /25 % Eto Ac /Hex ) to afford
0.0267 g of the carboxylic acid 3 (87 % ) as a colorless oil:
R = 0.16 (25 % EtOAc/Hex ); IR (ZnSe, cm ) 3322 (br),
2926 , 2856 , 1776 , 1709, 913 , 749 cm - ; 'H NMR : 8
3.28-3.18 (br m , 1H ), 3.13 /3.09 (overlapping dd, J= 9.6 , 3.1
and 9.0 , 3.5 , 0.56H /0.44H ), 2.50 /2.46 (two app abnormal
shape quintets, 0.55H /0.52H ), 2.42 (br dd , J= 9.6 , 4.5 Hz,
1H ), 2.35 /2.34 (two app t, J = 7.45 Hz, 2H ), 1.63-1.54 (br m ,
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4H ), 1.43-1.18 (br in , 22H ), 0.88 /0.87 (overlapping br t, 4 -octylcyclobutanone (OA7) was prepared based on a modi
J = 7.0 Hz, 3H ); 13C NMR: 8 212.1 , 179.9 , 62.0 /61.9 (two fication of a known procedure . To a solution of dichloroke
app s), 50.20 /50.17 (two app s ), 34.0 , 31.9 , 30.1, 30.1, 29.7 , tone OA2 (0.9917 g , 2.1mmol) in 4 mL of glacial acetic acid
29.6 , 29.6 , 29.4 , 29.3, 29.2 , 29.02 , 28.98 , 28.2 , 28.1 , was added Zn dust (0.1475 g , 23 mmol). [Note : The amount
28.0 , 27.6 , 24. , 24.3 , 24.3, 22.7 , 14.1; HREI-MS: calcd . 5 of Zn required depended upon the purity of the dichlorocy
for C20H360 Na, 347.2557 . Found [M +Na]": 347.2557 . clobutanone. In most cases, it was necessary to add a second
equivalent after approximately 12 h of reaction.] The mix
Purity > 97 % by HPLC (retention time, 6.82 min ).
2-(Octanoic acid benzyl ester, 8 -yl) 3 -octylcyclobutanol ture was stirred at rt under N2 until complete disappearance
and 3-(Octanoic acid benzyl ester, 8 -yl) 2 -octylcyclobutanol of the starting material was observed ( 16 h , TLC ). The
(OA ). To a -10 ° C.(ice/NaCl bath ) solution of the cyclobu- 10 reaction mixture was then cooled in an ice bath and diluted
tanone OA5 (0.037 g , 0.07 mmol) in anhydrous MeOH ( 1.5 with water (20 mL ). The resulting solution was extracted
mL ) was added NaBH4 (0.005 g , 0.15 mmol) under N2. The with EtOAC ( 3x50 mL ) and the combined organic layers
reaction mixture was stirred at -10 ° C. until no starting were washed sequentially with water (2x100 mL ) and
material remained on TLC ( 20 min ). The reaction was saturated NaHCO3 solution (2x50 mL ). The resulting
diluted with about 5 mL CH2Cl2 and quenched with 2 mL 15 organic layer was dried over Na2SO4 and concentrated under
sat. NaHCO3. The mixture was stirred for 10 min . The reduced pressure to furnish a colorless oil (0.8948 g, 97 %
organic layer was removed and the aqueous layer was crude yield ) as a 1: 1 mixture of regioisomers, each a 9: 1
extracted with CH C12 (3x5 mL ). The organic layers were mixture of cis / trans stereoisomers (' H NMR ); the mixture
combined , dried over with Na2SO4, and evaporated to afford was used directly in the next step . Analysis of the 'H NMR

the alcohol as a colorless oil (0.029 g, 99 % ). Although the 20 indicated that the expected product was accompanied by
crude product appears pure by 'H NMR , it is actually a recovered starting material OA2 (approximately 14 % ) and
mixture of two regioisomers, each a 70:30 mixture of the the cyclobutanone OA5 (overreduction product , approxi
1,2,3 -cis/cis and the 1,2 - trans -2,3 -cis isomers ( isomer iden mately 10 % ). These byproducts could not be removed by
tities established through 2D -NMR ). The individual isomers flash chromatography. R = 0.58/0.53 (major), 0.48 /0.43 (mi
can be detected by TLC in 20 % EtOAc/Hex : R = 0.50 25 nor) (10 % EtoAc in Hex ); IR (ZnSe , cm !) 3036 , 2925 ,
(major, all cis), 0.45 (major, all cis), 0.39 (minor, OH is trans
to backbone ), and 0.37 (minor, OH is trans to backbone); IR
( ZnSe, cm-?) 3396 (br), 2922 , 2852 , 1737 , 1156 , 732 , 696
cm-'; 'H NMR : 8 7.39-7.28 (br m , 5H ), 5.14 (s, 2H ), 4.23
br q , J= 7.3 , 0.714 ), 3.93 (br q , J= 7.3 , 0.3H ), 2.42-2.36 30

2854 , 1789, 1735, 1456 , 1162, 696 cm-'; 'H NMR: 8
7.36-7.25 (m , 5H ), 5.12 / 5.11 (overlapping s, 2H ), 4.97 (dd ,
J = 2.6 , 9.5 , 0.1H ), 4.51 (dd , J = 2.8 , 7.6 Hz, 0.9H ), 3.35-3.20
(m , 1.1H ), 2.75-2.65 (m , 0.1H ), 2.53-2.40 (m , 0.9H ), 2.36 /
2.35 (overlapping t, J= 7.2 Hz, 2H ), 1.75-1.20 (m , 26H ),

m , 1H ), 1.90-1.78 (br m , 1H ,), 1.70-1.60 (br m , 2H ),
1.60-1.48 br m , 2H ), 1.45-1.20 (br m , 22H ), 0.90 (br t, J = 7.6 ,

128.5 , 128.1, 66.0 , 65.7 , 58.3 , 58.2 , 40.74 /40.72, 34.18 ,
31.77 / 31.75 , 29.5 , 29.3 , 29.24 , 29.16 , 29.14 , 29.13 , 29.02 ,

(overlapping signal, 1H ), 2.37 (t, J= 7.6 , 2H ), 2.15-1.95 (br

0.92-0.85 ( m , 3H ); 13C NMR 8 203.48 /203.45, 173.5 , 136.1,

2H ); 13C NMR : 8 173.68 / 173.65 (overlapping ), 136.1, 28.97, 28.90 , 28.86 , 28.02 , 27.96 , 27.92, 27.87 , 25.64 /25.57 ,
128.5, 128.1 , 72.2 , 66.09/66.06 (two overlapping s), 66.0 , 35 24.80 /24.78 , 22.59/22.58 , 14.0 ; HRESI-MS : calcd . for
43.97 /43.95 (overlapping ), 37.3, 34.3 , 31.9, 30.7 , 30.6 , 30.2 , C27H4102C1Na, 471.2642. Found [M + Na]*: 471.2635 .
29.94 , 29.87 , 29.8 , 29.7 , 29.62, 29.58 , 29.5 , 29.33 , 29.29 ,
2 - Chloro - 4-( octanoic acid , 8 -yl) 3 -octylcyclobutanone-;
29.2 , 29.14 , 29.08, 29.0 , 27.7 , 27.6 , 24.90 , 24.88, 23.4 , 23.3 , 2 -Chloro - 3-(octanoic acid , 8 -yl) 4 -octylcyclobutanone (5 )
22.7, 14.1 ; HRESI-MS: calcd . for C27H4403Na, 439.3188. was prepared in a similar manner as compound 2. The
Found [ M + Na]+ : 439.3174 .
40 benzyl ester OA7 (0.085 g, 0.19 mmol), 10 % Pd /C (0.040 g ,
2-(Octanoic acid , 8- yl) 3 - octylcyclobutanol and 3-(Oc 0.038 mmol) and EtOAC (1.9 mL ) were used to afford
tanoic acid , 8 -yl) 2 -octylcyclobutanol (4) were prepared as 0.0478 g of the unprotected acid 5 (70 % ) as a colorless oil
a mixture (0.0158 g , 81 % ) from benzyl ester(s) OA6 (0.0247 after purification by flash column chromatography ( 20 %
g , 0.06 mmol), 10 % Pd/ C (0.0126 g , 0.012 mmol) and EtOAc/Hex ). The product also contain approximately 5 % of
EtOAc ( 0.6 mL) using a similar procedure as described for 45 an inseparable trans-chlorocyclobutanone 7 byproduct ('H
compound 2. Although the product, which is a colorless oil, NMR signal at 8 4.37) probably arising from the epimeriza
is assumed to be a similar mixture of regio- and stereoiso tion of cis - chlorocyclobutanone 5 : R , 0.19 (4:1 Hex: E
mers as was present in the benzyl ester precursor, the TOAc); IR ( ZnSe , cm-?) 3036 , 2924, 2854, 1788 , 1706 , 1461

individual isomers are not separable : R = 0.32 (4 :6 :0.05 of cm - 1; +H NMR : d 10.74 (br s, 1H , COOH ), 4.96 (dd , J= 9.4,
EtOAc:Hex :AcOH ); IR (ZnSe, cm-?) 3309 (br), 2922,2853 , 50 2.6 , 0.05H ), 4.50 (dd , J= 7.6 , 2.8 , 0.95H ), 3.35-3.20 (m ,
1709 cm - 1; ' H NMR : 8 4.22 (9 , J= 7.6,0.7H , assumed OH 1.05H ), 2.46 (quintet, J= 8.1 , 0.95H ), 2.74-2.62 (m , 0.05H ),
is cis to backbone from the characterization of starting 2.35/ 2.33 (overlapping t, J= 7.3 , 2H ), 1.80-1.15 (m , 22H ),
material ), 3.92 (q, J= 7.6 , 0.3H , assumed OH is trans to 0.88/0.87 (overlapping t, J= 6.9, 3H ); 13C NMR 8 203.62 /
backbone ), 2.43-2.33 (br m , 1H ), 2.34 (t, J= 7.3 , 2H ), 2.18
203.56 , 180.1, 65.7 , 58.30 /58.26 , 401.8 , 34.0 , 31.8 , 29.5 ,
1.92 (m ), 1.84 (br septet, J = 8.0 , 1H ), 1.68-1.58 (br quintet, 55 29.4, 29.3 , 29.18 /29.15 , 29.04 /29.00 , 28.9, 28.04 /27.98 ,
J = 7.0 , 2H ), 1.58-1.48 (br m , 2H ), 1.43-1.18 (br m , 22H ), 27.95 / 27.90 , 25.67/25.59, 24.5 , 22.6 , 14.1; HRESI-MS:
0.88 (br t, J= 7.0 Hz, 3H ); 13C NMR : 8 179.50 /179.46 (two calcd . for C20H3502C1Na, 381.2172 . Found [M + Na] *:
app s), 72.28, 66.16 /66.12 ( two app s), 48.87/48.79 (two app 381.2191.
s ), 43.97, 37.26 , 35.06 , 33.98 , 31.89 , 30.69 /30.62, 30.24,
(E )-9- octadecenoic acid , benzyl ester (benzyl elaidate )
30.18, 29.90 , 29.87, 29.79, 29.74 , 29.63 , 29.60 , 29.51, 60 was prepared from the reaction of elaidic acid (0.9836 , 3.5
29.46 , 29.34, 29.31, 29.21, 29.11 , 29.06 , 29.01, 28.99,
28.97, 28.67, 28.60 , 28.05 , 27.95 , 27.92 , 27.73 , 27.60 ,
24.66 / 24.63, 23.38/ 23.34 , 22.67, 14.10 ; HRESI-MS: calcd .

mmol), DCC (0.79 g , 3.8 mmol), DMAP (0.087 g , 0.7
mmol), and benzyl alcohol (0.73 mL , 7 mmol) in CH2Cl2
( 10 mL ) by a similar procedure as employed for benzyl

for C20H3 :03Na, 349.2719. Found [M + Na ]*: 349.2715. oleate . The product was purified by flash column chroma
Purity > 99 % by HPLC (retention time, 11.8 and 15.9 min ). 65 tography on silica gel ( 2.5 % / 5 % EtOAc /Hex ) to afford
2 - Chloro -4-(octanoic acid benzyl ester, 8 - yl)-3 - octylcy
1.2280 g (95 % ) ofbenzyl elaidate as a colorless oil:Rf= 0.57
clobutanone ; 2 -Chloro - 3-(octanoic acid benzyl ester, 8 -yl) ( 10 % EtOAc/Hex ). IR (ZnSe, cm - 1) 2922 , 2852 , 2737 ,
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1160, 966 , 696 cm-'; ' H NMR : 8 7.38-7.34 (m , 5H ),
5.41-5.38 (m , 2H ) , 5.13 (s, 2H ), 2.37 (t, J= 7.2 Hz, 2H ), 1.98
(br s , 4H ), 1.68-1.63 (m , 2H ), 1.38-1.18 (br m , 20H ), 0.90

31.9, 31.3 , 29.7 , 29.5 , 29.4 , 29.3 , 29.0 , 27.7 , 27.5 , 26.6 , 24.9 ,
22.7, 14.1; HRESIMS : calcd . for C2H400 , C12: [ M +Na ]*
507.2409. Found : 507.2409 .

(t, J= 7.2 Hz, 3H ); 13C NMR 8 173.6 , 136.1 , 130.4, 130.2 ,
first- eluting H. -H , cis : R = 0.61 ; IR (ZnSe, cm ): 3448
128.5 , 128.1 , 66.0, 34.3, 32.57, 32.52, 31.9 , 29.6 , 29.52 , 5 (br), 2925 , 2854, 1737, 1456 , 1163 , 734 , 697 cm -l; ' H
NMR: 8 7.37-7.31 (m , 5H ), 5.12 (s, 2H ), 3.91 (dd ,
29.46 , 29.3 , 29.2 , 29.1 , 29.0 , 28.9 , 24.9 , 22.7, 14.1.
J 11.02-10.8 Hz, 211,14(trans)= 8.0 Hz, 4J11,H3( cis) =0 Hz ,
2,2 -Dichloro -4-(octanoic acid benzyl ester, 8 - yl) 3 -octyl
cyclobutanone-; 2,2 -Dichloro - 3-(octanoic acid benzyl ester, 1H , CH - OH ), 2.46 (d , J = 10.8 Hz, 2H , OH ), 2.36 (t, J= 7.6
8 -yl) 4 -octylcyclobutanone (EA2) was prepared based on a Hz, 2H ), 2.11-2.04 (m , 1H , CH CCl2), 1.75-1.18 (m , 27H ),

known procedure. To a mixture of Zn (Cu ) ( 1.8443, 28 10 0.88
(t, J=6.8 Hz, 3H ); 13C NMR , 75MHz: 8 173.6, 136.1,
128.5 , 128.2 , 91.0 , 81.6 , 66.1 , 51.9 , 48.1 , 34.3 , 33.0 , 31.8 ,

mmol) and benzyl elaidate EA1 ( 2.073 g , 5.6 mmol) in 11
mL of anhydrous ether was added over 2 h (syringe pump )
trichloroacetyl chloride (2.0 mL , 18 mmol). The reaction
mixture was stirred at rt for 5 h (or until the starting material
is consumed by TLC ) and filtered through a plug of Celite .
The residue was washed with ether (20 mL ) . The combined
ether layers were transferred to a round bottom flask and

30.0 , 29.6 , 29.41, 29.38, 29.2 , 29.0 , 27.3 , 26.8 , 24.9 , 22.6 ,

14.1; HRESIMS: calcd . for C27H4003C12 : [M + Na]*

507.2409 . Found : 507.2415 .
15

Second - eluting H.-H , trans: R = 0.56 ; IR (ZnSe , cm '):

3463 (br), 2925 , 2854, 1736 , 1456 , 1163 , 696 cm ; ' H
NMR : d 7.36-7.31 (m , 5H ), 5.11 (s, 2H ), 4.40-4.34 (m , 1H ),
2.64-2.55 (m , 1H , CH - OH ), 2.64-2.55 ( m , 1H , CH
cooled over ice . The black solution was then diluted with 40
CCl2), 2.46 (d , J = 4.8 Hz, 1H , OH ), 2.35 (t, J = 7.6 Hz, 2H ),
mL of water and 40 mL of sat. NaHCO3. The mixture was 20 2.20-2.03 (m , 1H , CH - CHOH ), 1.80-1.10 (br m , 26H ),
allowed to warm to rt and stirred overnight. The aqueous 0.88 (t, J= 6.4 Hz, 3H ); 13C NMR , 75 MHz: 8 173.7 , 136.1 ,
layer was extracted with ether ( 3x50 mL ) and the combined 128.5 , 128.2 , 90.2 , 78.4 , 66.1 , 57.0 , 42.0 , 34.3 , 31.9, 31.3 ,
organic layers were dried over Na2SO4 and evaporated to 29.6 , 29.5 , 29.41, 29.39, 29.2 , 29.1 , 29.0 , 27.6 , 27.5 , 26.7 ,
dryness . The residue obtained upon concentration could be 24.9 , 22.7 , 14.1; HRESIMS: calcd . for C27H4003Cl2 :
used for the next step without further purification or, alter- 25 [M +Na] +507.2409. Found : 507.2398 .
natively, could be purified by rapid flash column chroma
Second -eluting H.- H , cis : R = 0.51 ; IR (ZnSe, cm-');
tography through a short plug of silica (2.5 % /5 % EtoAc/ 3444 (br), 2924 , 2854 , 1734 , 1162 , 734, 696 cm - 1; 1H NMR :

Hex ) to afford 1.6856 g (63 % ) of a yellow oil consisting of (57.37-7.31 (m , 5H ), 5.11 (s, 2H ), 3.90 (dd , 3JH1
, ,OH = 10.8
a 1: 1 mixture of regioisomers: R = 0.63 (20 % EtOAc/Hex ); Hz, 3JH1,H4(trans
trans )) = 8.0 Hz, 4JH1 ,H3 ( cis ) = 0 Hz, 1H , CH - OH ) ,
IR (ZnSe, cm - 1) 2926 , 2855 , 1802 , 1735 , 1456 , 1162 , 696 30 2.52 (OH , d , J= 10.8 Hz, 2H ), 2.35 (t, J= 7.6 Hz, 2H ),
cm '; 'H NMR : 8 7.47-7.23 (m , 5H ), 5.120 /5.117 (overlap 2.13-2.02 ( in , 1H , CH - CC12), 1.75-1.18 (m , 27H ), 0.89 (t,

ping s, 2H ), 3.158 /3.126 (overlapping dt, J= 7.2 , 1.5 Hz, 1H ),

J = 6.8 Hz, 3H ); 13C NMR, 75 MHz: 8 173.7 , 136.1 , 128.5 ,

22.59, 22.57 , 14.04 , 14.03 ; HRESI-MS : calcd . for

tanoic acid benzyl ester, 8 -yl) 4 -octylcyclobutanol, meth

5.12 (s, 2H ), 4.37 (br d , J = 6.4 Hz, 0.4H ), 3.91 (br d , J = 8.0
Hz, 0.6H ), 2.80-2.45 (br m , 211), 2.37 /2.36 (overlapping t,
J= 7.6 Hz, 2H ), 1.80-1.05 (br m , 26H ), 0.89 /0.88 (overlap
ping t, J= 6.7 Hz, 3H ). Small quantities of individual isomers 55
could be separated for analysis by flash column chromatog
raphy using 10 % EtOAc/Hex . The stereochemical assign
ments were assigned by 2D -NMR experiments including
COSY, NOESY, and HSQC .
first-eluting H ,-Hz trans: R = 0.66 ; IR (ZnSe, cm-?): 3463 60
(br), 2927, 2855 , 1738, 1453, 1158 cm - l; ' H NMR : 8
7.37-7.31 (m , 5H ), 5.12 (s, 2H ), 4.38 (ddd , ' JH1
, ,H4 =6.8 Hz,
3J41,0H =5.1 Hz, 4JH1H3(trans)= 1.3 Hz, 1H , CH - OH ), 2.62

(two overlapping s , total 1.2H ), 2.66-2.58 (m , 0.4H ), 2.40
2.30 (m , 2H ), 2.21-2.12 (m , 0.6H ), 2.10-1.98 (m 0.6H ),
1.80-1.15 (m , 26.4H ), 0.91-0.86 (m , 3H ); 13C NMR 8 173.6 ,
136.10 /136.08 , 128.5 /128.1 , 86.45 /86.38 , 84.09, 83.86 /
83.82, 66.03 /66.01, 57.18 , 51.81/ 51.80 , 44.51/44.50 , 41.71,
39.5 , 39.0 , 34.2 , 32.21/32.18 , 31.78/31.77, 31.41/31.36 ,
30.1 , 29.49 29.46 , 29.42, 29.34 , 29.32 , 29.27, 29.22 , 29.16 ,
28.95 , 28.90 , 28.2 , 27.0 , 26.9 , 26.8 , 26.7 , 26.6 , 26.5 , 26.4 ,
26.3, 24.8, 22.6 , 14.1; HRESI-MS: C28H4403C1,SNa:
[M + Na] 585.2184. Found : 585.2186 .
1- (Octanoic acid , 8 -yl)-2 -octylcyclobutene (6 ) was pre
pared similarly to compound 1 from reductive fragmentation

1.80-1.10 (br m , 26H ), 0.89 (t, J = 6.7 Hz, 3H ); 13C NMR: 8
173.6 , 136.1 , 128.5 , 128.2 , 90.2 , 78.5 , 66.1, 57.0 , 42.0 , 34.3 ,

mmol). The crude productwas purified by flash chromatog
raphy ( 10 % EtOAc/Hex ) to afford the acid 6 (0.0352 g ,

2.56-2.46 (m , 1H ), 2.37/2.34 (overlapping t, J= 7.6 Hz, 2H ),
.1, 91.0 , 81.6 , 66.1 , 51.9 , 48.0 ,
33.0 , 31.8 , 30.0 ,
1.96-1.18 (m , 26H ), 0.90 /0.87 (overlapping t, J= 7.2 Hz, 3H ); 29.6 , 29.4 , 29.3 , 29.2 , 29.02, 28.97 , 28.9 , 27.2 , 26.8 , 24.9 ,
13C NMR , 75 MHz: d 196.3 , 173.5 , 136.0 , 128.4 , 128.1 , 35 24.8 , 22.6 , 14.1; HRESIMS: calcd . for C2 H4002Cl2:
87.1, 66.0 , 60.7, 60.6 , 52.3 , 34.2 , 34.1 , 31.8, 31.7, 31.37 , [M +Na ] 507.2409. Found: 507.2409.
31.36 , 29.42, 29.40 , 29.3 , 29.23 , 29.20 , 29.14 , 29.12 , 29.08,
2,2 -Dichloro -4-( octanoic acid benzyl ester, 8 -yl) 3 -octyl
28.93 , 28.90 , 28.85 , 27.5 , 27.4 , 27.12 , 27.05, 24.80 , 24.78 , cyclobutanol, methanesulfonate ester ; 2,2 -Dichloro - 3-(oc

C2H400 , C1,Na [M +Na] *: 505.2252 Found: 505.2248 . 40 anesulfonate ester (EA4 ) was prepared similarly to OA4
2,2- Dichloro -4 - octanoic acid benzyl ester, 8 -yl) 3 -octyl from reaction of methanesulfonyl chloride (0.05 mL, 0.7
cyclobutanol; 2,2 -Dichloro - 3-(octanoic acid benzyl ester, mmol), cyclobutanol EA3 (0.1659 g , 0.3 mmol), and trieth
8 -yl) 4 -octylcyclobutanol (EA3) was prepared by a similar ylamine (0.20 mL, 1.7 mmol) in CH2C12 (2 mL ). The crude
procedure as OA3. Dichlorocyclobutanone EA2 (0.2100 g, product was purified by flash chromatography ( 5 % EtOAc/
0.4 mmol), NaBH4 (0.055 g , 1.5 mmol), and iProH 6 mL 45 Hex ) to provide dichloro mesylate EA4 as a light yellow oil
was obtained the product purified by flash column chroma (0.1456 g , 86 % ) which included several inseparable iso
tography with 5 % EtOAc/Hex to afford the mixture of 1 : 1 mers : R = 0.40 /0.38 ( 20 % EtOAc/Hex ); IR (ZnSe, cm- ):
regioisomer EA3 0.1659 g (85 % ) as a colorless oil: R ,-0.66 2925, 2851, 1734 , 1368 , 1180 , 964 , 697 cm-?; H NMR : 8
(minor )/0.61 (major)/0.56 (minor )/0.51 (major ) ( 10 %
7.38-7.30 (m , 5H ), 5.20 (dd , J = 7.1, 1.2 Hz, 0.4H ), 5.115 /
EtOAc/Hex ). IR ( ZnSe , cm-?): 3459 (br ), 2924 , 2853 , 1736 , 50 5.112 ( two overlapping s, total 2H ), 4.84 (d , J= 8.8 Hz,
1456 , 1161 , 734 , 696 cm-?; ' H NMR : 87.36-7.31 (m , 5H ), 0.6H ), 3.202/3.199 (two overlapping s, 1.8H ), 3.166 / 3.163

2.55 (m , 1H , CHCC12 ), 2.44 (d, °JH1,01 = 5.1 Hz, OH ), and deprotection of dichloromethansulfonate EA4 (0.1430 ,
2.36 (t, J = 7.6 Hz, 2H ), 2.18-2.08 (m , 1H , CH CHOH ), 65 0.25 mmol) in THF ( 1 mL ), NH3 (~ 10 mL ), Na (-0.09 g, 4.1
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46 % ) as a colorless oil : R = 0.35 (60:40 of Hex :EtOAC ); IR
(ZnSe , cm-?) 3124 , 2923 , 2852 , 1708 , 910 , 736 cm - 1; ' H

until the starting material was consumed ( TLC , 24 h ). The
reaction was concentrated and the residue redissolved in
NMR : 8 6.12 (br s, 2H ), 2.35 (t, J= 7.2 Hz, 2H ), 2.26 (t, J= 7.2 toluene (400 mL ) and triethylamine (8.5 mL). The solution
Hz, 2H ), 1.64 (quintet , J= 7.2 Hz, 2H ), 1.44 (br m , 4H ) , was stirred for 24 h and washed with water. The aqueous
1.35-1.20 (23H ), 0.88 (t, J= 6.8 Hz, 3H ); 13C NMR 8 179.7 , 5 layer was then extracted with ether. The combined organic
139.2 , 139.1 , 50.4 , 50.3 , 34.02 , 33.97 , 31.9 , 29.9 , 29.6 , 29.3 ,
29.2 , 29.0 , 28.4 , 28.3 , 24.7 , 22.7 , 14.1 ; HRFAB -MS ( 3 -NBA
matrix ): calcd . for C20H3502Li2 321.2957. Found [M - H +
2Li]*: 321.2969 . Purity 100 % by HPLC (retention time,
4.73 min ).
2 -Chloro -4-(octanoic acid benzyl ester, 8 -yl) 3 -octylcy
clobutanone-; 2 -Chloro - 3-(octanoic acid benzyl ester, 8 -yl)

10

solution were combined , dried with Na2SO4, and concen
trated under vacuum . The residue was purified by flash
column chromatography on silica gel (5-10 % EtoAc in
Hex ) to give benzyl 9 -decenoate DA1 ( 13.1 g, 99 % ) as a
colorless oil: R -0.40 ( 10 % EtOAc/Hex ); IR (ZnSe, cm !):
3072, 2927, 2855 , 1734 , 1161, 908, 730 cm-?; ' H NMR : 8
7.38-7.32 (m , 5H ), 5.83 (ddt, J = 17 , 10.2 , 6.6 Hz, 1H ), 5.14

4 -octylcyclobutanone EA5 was prepared similarly to the (s, 2H ), 5.02 (ddd , J= 7.6 Hz, 2H ), 5.00 (dq , J= 17.0 , 1.7 Hz,
procedure described for compound OA7. Reaction of benzyl 1H ), 4.96 (d of quintet, J = 10.2 , 1.2 Hz, 1H ), 2.37 (t, J= 7.3
ester EA2 (0.50 g , 1.0 mmol), Zn (Cu ) (0.0744 g, 1.1 mmol) 15 Hz, 2H ), 2.10-2.02 (br q , J= 7.3 Hz, 2H ), 1.70-1.63 (br m ,
and glacial acetic acid (2 mL ) furnished, after flash chro
2H ), 1.41-1.48 (m , 10H ); 13C NMR : 8 173.5 , 138.9 , 136.1 ,
matography (5 % EtoAc/Hex ), trans-monochlorocyclobu
128.4 , 128.1, 128.0 , 114.1 , 65.9 , 34.2 , 33.7 , 28.99 , 28.97 ,
tanone EA5 (0.3126 g , 70 % ) as a colorless oil which 28.8 , 28.7 , 24.8 , 22.6 , 14.0 ; HRESI-MS: calcd . for
included an equal mix of the 2 -chloro -4 -octyl and 2 -chloro
C17H240 Na: [ M + Na]* 283.1674 . Found: 283.1671.

3 -octyl regioisomers , each of which included both epimers 20 3-(Octanoic acid, 8 -yl, benzyl ester ) 2,2 - dichlorocyclobu
at the chloride-bearing carbon : R = 0.42/0.39 (minor) and tanone DA2 was prepared similarly to compound OA2 and

afforded ( 13.78 g , 80 % ) as a brown oil from benzyl 9 -de
0.33 (major ) ( 10 % EtOAc /Hex ).
The amount of Zn dust varied from 1.1-2.2 equiv ; gen cenoate DA1 ( 12.36 g, 48 mmol), trichloroacetyl chloride
erally , a second equivalent of zinc dust was added to the (10.7 mL , 95 mmol), and Zn (Cu) (15.55 g , 238 mmol) in
incomplete reaction mixture after stirring for approximately 25 ether 0.1 M (340 mL ) (Consistent with a previous report ,
12 h . The residual dichlorocyclobutanone was easily only one isomer was observed . The assignment was con
removed by flash column chromatography. However, the firmed by presence of geminal hydrogens adjacent to the
cyclobutanone product of overreduction was formed in ketone alpha ketone position at 8 3.33 and 2.94 by 'H -NMR
significant amounts (28 % based upon ' H NMR and was and by the observation of eleven rather than twelve carbons
nearly inseparable by flash column chromatography : IR 30 ( symmetry ) upon dechlorination to cyclobutanone 10 ):
(ZnSe, cm - 1) 2924 , 2854 , 1788 , 1735, 1457, 1161, 733 ,696 R = 0.34 (10 % EtOAc/Hex ); IR (ZnSe, cm ): 2935 , 2852 ,
cm-?; ' H NMR: 87.40-7.32 (m , 5H ), 5.113/ 5.110 (overlap
1814 , 1730 , 905 , 725 cm - 1; ' H NMR : 8 7.39-7.29 (m 5H ),
ping s, 2H ), 4.95 (dd , J= 3.1 , 9.4 , 0.3H ), 4.37 (dt, J = 2.7 , 7.8
Hz, 0.7H ) , 2.97-2.90 (m , 0.3H ), 2.84-2.74 (m , 0.7H ), 2.40

5.12 (s, 2H ), 3.33 (dd, J= 9.4 , 17.2 , Hz, 1H ), 2.94 (dd, .0 ,
17.2 Hz, 1H ), 2.88-2.81 (m , 1H ), 2.37 /2.36 (overlapping t,

2.30 (overlapping m , 2.3H ), 2.08-1.97 (m , 0.7H ), 1.85-1.10 35 J= 7.5 Hz, 2H ), 1.94-1.84 (m , 1H ), 1.70-1.72 (m , 3H ),
(m , 26H ), 0.92-0.84 (m , 3H ); 13C NMR 8 204.6, 202.0 , 1.46-1.28 (m , 8H ); 13C NMR 8 192.8 , 173.4 , 136.0, 128.4 ,
173.5 , 136.1 , 128.5 , 128.1, 66.0 , 65.52 /65.46 , 63.98 , 63.78 /

128.0 , 88.8 , 65.9 , 47.7 , 45.8 , 34.1, 31.2 , 29.0 , 28.9 , 28.8 ,

63.75 , 63.57 /63.52, 60.74/60.69 , 49.8 , 43.7 , 37.4 , 36.63 /

27.2 , 24.7 ; HREI-MS: calcd . for C19H2503C12: [M + H ]*

28.88, 28.2 , 27.67, 27.60 , 27.55 , 27.48 , 27.38 , 27.3 , 27.2 ,
27.1 , 24.83 / 24.80 , 22.6 , 14.0 ; HRESI-MS: calcd . for
C27H4102C1Na, 471.2642 . Found [M + Na]*: 471.2630 .
2-Chloro -4 - octanoic acid , 8 - yl) 3 -octylcyclobutanone-;

tanol DA3 was prepared similarly to compound 0A3 from
the previous dichloroketone DA2 (10.0 g, 26.9 mmol),
NaBH4 (1.528 g, 40.4 mmol), and iProH (350 mL ). The
crude product was purified by flash column chromatography

36.59 , 35.12 /35.10 , 34.2 , 31.8 , 31.3 , 30.3 , 30.1 , 29.5 , 29.42 , 371.1181. Found: 371.1188 .
29.38 , 29.32 , 29.25 , 29.19 , 29.03 , 29.00 , 28.96 , 28.93 , 40 3- (Octanoic acid , 8 -yl, benzyl ester) 2,2 -dichlorocyclobu

2 - Chloro -3-(octanoic acid , 8 - yl) 4 -octylcyclobutanone (7 ) 45 with 10 % EtOAc/Hex to furnish the dichlorobutanol DA3
was prepared similarly to compound 2. Reaction of benzyl (5.76 g , 57 % ) as a colorless oil: R = 0.39 ( 20 % EtoAc/Hex );
ester EA5 (0.0337 g , 0.11 mmol), with 10 % Pd / C (0.0236 g , IR (ZnSe , cm-?): 3440 (br ), 2927, 2854 , 1733 , 1164, 960,
0.022 mmol) and EtoAc (1 mL ) afforded 0.0127 g of the 697 cm '; 'H NMR : 8 7.40-7.30 (m 5H ), 5.12 (s, 2H ),
unprotected acid (54 % ) as a white solid : R = 0.24 (6:4:0.05 4.73-4.64 (m , 0.1H ) 4.34-4.27 (m , 0.9H ), 2.97 (d , J = 8.2 Hz,
of Hex: EtOAc: AcOH ); mp.= 74-75 ° C .; IR (ZnSe, cm ') 50 0.1H , OH is trans to backbone ), 2.87 (d , J= 10.3 Hz, 0.9H ,

3062, 2924, 2854, 1789, 1708, 1464 cm - 1; ' H NMR : 8 8.70 OH is cis to backbone ), 2.48-2.34 (m , 1H ), 2.36 (t, J= 7.6 Hz,
(br s, 1H ), 4.95 ( dd , J = 2.9, 9.2 , 0.3H ), 4.37 (ddd , J= 7.8 , 2.5 , 2H ), 1.78-1.60 (m , 3H ), 1.53-1.28 (m , 11H ); 13C NMR S
1.3 , 0.7H ), 2.97-2.91 ( m , 0.3H ), 2.85-2.73 (m , 0.7H ), 2.40
173.7 , 136.0 , 128.5 , 128.1, 92.9 , 75.4 , 66.1, 45.6 , 34.5 , 34.2 ,
2.22 (m , 22H ), 2.11-2.98 (m 0.7H ), 1.85-1.10 (m 26H ), 29.8 , 29.2 , 29.0 , 28.9 , 26.5 , 24.8 ; HRESIMS: calcd . for
0.92-0.82 (m , 3H ); 13C NMR 8 211.7, 204.7, 202.2, 179.9, 55 C19H2302Cl2: [M +Na ]* 395.1157 . Found: 395.1151.
65.6 /65.5 , 64.0 , 63.85 /63.82 , 63.64 /63.58 , 60.82 /60.77,
3-(Octanoic acid , 8 -yl, benzyl ester) 2,2 - dichlorocyclobu
49.81, 43.8 , 37.5 , 36.69/ 36.65 , 35.2 , 34.0 , 31.8 , 31.3 , 30.4 , tanol,methanesulfonate ester DA4 was prepared similarly to
30.2 , 29.55, 29.48 , 29.44, 29.38 , 29.31, 29.25 , 29.2 , 29.06 , compound OA4 from reaction ofmethanesulfonyl chloride
29.06 , 28.9 , 28.3 , 28.2 , 27.73, 27.67, 27.62, 27.44, 27.37, (20 mL , 29.4 mmol), cyclobutanol DA3 (5.50 g, 14.7
27.26 , 27.20 , 27.17 , 24.63/24.60 , 22.7 , 14.1 ; HRESI-MS: 60 mmol), and triethylamine (9.2 mL , 66.3 mmol) in CH C12
calcd . for C20H350 , CIN , 381.2172 . Found [ M +Na]* : (70 mL ). The crude product was purified by flash chroma
381.2170 .
tography ( 10 % EtoAc /Hex ) to afford DA4 as a light yellow

Benzyl 9- decenoate (DAI) was prepared by a known
procedure.' Thionyl chloride (36.9 mL, 51 mmol)was added

oil (6.1340 g, 92 % ): R = 0.36 ( 20 % Eto Ac /Hex ); IR ( ZnSe,
cm-?): 2927 , 2858 , 1731, 1364 , 1179 , 952 cm-'; 'H NMR:

mmol) in toluene (400 mL ). The reaction was stirred at rt

(m , 13H ); 13C NMR 8 173.5 , 136.0 , 128.4 , 128.1 , 88.4 , 78.3 ,

to a stirred solution of 9 -decenoic acid DA ( 8.67 g , 51 mmol) 65 87.36-7.31 ( m 5H ), 5.11 (s , 2H ), 5.13-5.09 (m , 1H ), 3.18 (s ,
and catalytic dimethylformamide (DMF, 0.12 mL , 1.5 3H ), 2.56-2.50 (m , 2H ), 2.35 (t, J = 7.6 Hz, 2H ), 1.93-1.28
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66.0 , 45.8 , 39.3 , 34.1, 31.6 , 29.8 , 29.1, 28.87 , 28.85 , 26.2 ,
24.8 ; HRESI-MS: calcd . for C2H280 C1, SNa: [M +Na ]*

were used to afford 0.0395 g (76 % ) of S15 (a mixture of 9 :1
of the stereoisomer, predominantly as the cis diastereomer

based on previously assigned for cyclobutanol 4 ) as a
8-(2 - Cyclobuten -1 -yl)-octanoic acid ( 8) was prepared by low -melting white solid : R = 0.29 (20 % EtOAc/Hex );
a similar procedure as 1 from reaction of Na metal (2.8 g, 5 m.p.= 30-31° C .; IR (ZnSe, cm -1) 3356 (br), 2922, 1734 ,
120 mmol) with a solution of 5.4 g ( 12 mmol) of the mixture 1154 , 735 ,696 cm-?; ' H NMR : 8 7.40-7.30 (m , 5H ), 5.11 (s,

473.0932. Found : 473.0930 .

of dichloro mesylate DA4 in THF (30 mL ) and NH3 (~ 250 2H ), 4.42-4.34 (br m , 0.1H ), 4.14-4.03 (br m , 0.9H ), 2.48
mL ). The crude product was purified by flash column 2.40 (m , 0.18H ), 2.35 (t, J= 7.2 , 0.18H ), 2.16-2.04 ( m ,0.2H ),
chromatography (2 % EtOAc/Hex ) to afford 9,10 - ethenooc
1.95 (t, J = 6.6 , 0.2H ), 1.70-1.56 (br m , 3H ), 1.48-1.13 (br m ,
tadecanoic acid (1.6367 g , 52 % ) as a low -melting white 10 12H ); 13C NMR : 8 173.6, 136.0, 128.4, 128.1, 66.0 , 63.7 ,
solid : R = 0.47 (6 :4 :0.05 of Hex :EtOAc : AcOH ); m.p. = 20 39.7 , 37.0 , 34.2 , 29.2 , 29.1, 29.0 , 27.3, 25.4 , 24.82 ; HRCI
21° C .; ÍR (ZnSe , cm-?) 3112 (br), 3043 , 2920 , 2853 , 1705 , MS : calcd . for C1,H2,02Na [ M + Na]" : 305.2117 . Found :
697 cm '; 'H NMR : d 10.27 (br s, 1H , COOH ), 6.11 (br d , 305.2116 .
J = 2.4 Hz, 1H ), 6.04 (br dd , J = 0.8 , 2.0 Hz, 1H ), 2.77 (m , 1H ),
3-(Octanoic acid ) cyclobutanol (11 ) was prepared simi
2.66 (ddd , J= 0.8, 4, 13.2 Hz, 1H ), 2.35 (t, J= 7.2 Hz, 2H ), 15 larly to compound 2. Benzyl ester DA6 (0.0337 g, 0.11
2.04 (d , J= 13.2 Hz, 1H ), 1.64 (quintet, J= 7.2 Hz, 2H ), mmol), 10 % Pd /C (0.0236 g , 0.022 mmol) and EtOAC (1
1.51-1.38 (br m , 2H ), 1.38-1.23 (br m , 8H ); 13C NMR 8 mL ) were used to afford 0.0127 g of the unprotected acid 11
180.0 , 141.1 , 135.1 , 44.2 , 36.9 , 34.6 , 34.0 , 29.5 , 29.2 , 29.0 , (54 % ) as a white solid : R = 0.24 (6 :4: 0.05 of Hex: EtOAc :
27.9, 24.7 ; HRESI-MS: calcd . for C12H200 Na [M + Na] *: AcOH ); m.p.= 74-75 ° C .; IR (ZnSe , cm-?) 3341 (br), 2916 ,
219.1361. Found : 219.1355 . Purity 100 % by HPLC (reten- 20 2849, 1695, 1064 cm-?; 'H NMR MOD
(
): 8 4.30 ( quintet,
tion time, 5.01 min ).
J = 6.8 , 0.1H ), 4.01 (quintet, J = 6.4 , 0.9H ), 2.45-2.35 (br m ,
8 - Cyclobutyloctanoic acid (9 ) was prepared by a similar 2H ), 2.29 (t, J = 7.2 , 2H ), 1.75-1.55 (br m , 3H ), 1.50-1.15 (br
procedure as for 2 from the hydrogenation of cyclobutene 8 m , 12H ); 13C NMR MOD
(
): 8 176.3, 62.8 , 38.9 , 36.9, 36.8 ,
(0.0339 , 0.17 mmol), over 10 % Pd/ C (0.0367 g , 0.03 mmol) 33.6 , 29.1, 29.0 , 28.8 , 27.1, 25.4 , 24.7 ; HRESI-MS: calcd .

in EtoAc ( 1.7 mL) to afford 0.0301 g ofthe unprotected acid 25 for C12H2203Na [M +Na]*: 237.1467. Found : 237.1460 .

9 (89 % ) as a low -melting white solid : R -0.47 (6 :4 :0.05 of Purity > 97 % by HPLC (retention time, 9.65 and 11.36 min ).
Hex : EtOAc :AcOH ); m.p.= 28-30 ° C .; IR (ZnSe , cm-?):
3035 (br ), 2916 , 2849 , 1695 , 909, 733 cm-?; ' H NMR : 8
Example 2 – Determination of Inhibitor Aqueous
Stability and Solubility
11.34 (br s, 1H , COOH ), 2.37 (t, J = 7.2 , 2H ), 2.25 ( septet,
J= 7.2 , 1H ), 2.10-1.98 (m , 2H ), 1.90-1.75 (m , 2H ), 1.70-1.52 30
(m , 2H ), 1.40-1.12 (br m , 10H ); 13C NMR : 8 180.3 , 37.0 ,
Although cyclobutenes are known to undergo thermally
36.2 , 34.1 , 29.4 , 29.2 , 29.0 , 28.4 , 27.1 , 24.7 , 18.5 ; HRCI
induced electrocyclic ring -opening , assessment of the ther
MS: calcd . for C12H2202: [M + H ]* 199.1698 . Found : mal stability of cyclobutene using differential scanning
199.1695. Purity > 99 % by HPLC (retention time, 4.92 min ). calorimetry (DSC ) and thermal gravimetric analysis (TGA )
3-(Octanoic acid benzyl ester, 8 -yl)cyclobutanone (DA5) 35 found no decomposition occurred at temperatures below
was prepared similarly to oleate series. Dichloroketone DA2 150° C. (FIG . 1 ).
( 1.05 g, 2.69 mmol), 6 mL of glacial acetic acid , and Zn (Cu )
One -dimensional ( 1D ) 'H -NMR spectroscopy was used to
( 1.76 26.9 mmol) were used and the product was purified verify the chemical purity, aqueous stability, and concentra
by flash chromatography (10 % EtOAc/Hex ) to afford col tion dependent micelle formation of eleven fatty acid ana
orless oil 0.4859 g (59 % ) as a mixture of isomers: R 0.55 40 logs. Each compound was dissolved in deuterated dimethyl
(20 % EtOAc/Hex ). IR (ZnSe, cm -1) 2923, 2854 , 2780 , sulfoxide (DMSO -do) to obtain a stock concentration of 20
2732 , 1163 , 730 , 697 cm - 1; ' H NMR : 8 7.35-7.28 (br m , mM . Four different concentrations were prepared from the
5H ), 5.09 (s, 2H ), 3.13-3.03 (m , 2H ), 2.65-2.57 (m , 2H ), stock solutions for NMR analysis : 1.00 mm , 750 uM , 500
2.33 (t, J= 7.2 , 2H ), 2.33-2.26 (m , 1H ), 1.68-1.58 (br quintet, uM , 100 uM . All NMR samples consisted of 600 uL of a
J = 6.4 , 2H ), 1.58-1.48 (br q, J= 7.2 , 2H ), 1.29 (br s, 8H ); 13C 45 deuterated 50 mM potassium phosphate buffer at pH 7.2
NMR : 8 208.2 , 173.3 , 134.0 , 128.3 , 127.9 , 65.8 , 52.3 , 36.1 , with 50 uM of 3 ( trimethylsilyl) propionic - 2,2,3,3 -d4 acid
34.0 , 28.9, 28.8 , 28.0 , 24.7 , 23.6 ; HRESI-MS: calcd . for sodium salt (TMSP ). Each 600 uL NMR sample contains 30
C19H2603Na [M + Na]*: 325.1780 . Found : 325.1775 .
uL (5 % ) of DMSO -do and was transferred to a 5 mm NMR
3-(Octanoic acid , 8 - yl)cyclobutanone ( 10 ) was prepared tube for analysis.
similarly to compound 2 : The benzyl ester DA5 (0.0346 , 0.1 50 A Bruker Avance DRX 500 -MHz spectrometer equipped
mmol), 10 % Pd /C ( 0.020 g , 0.02 mmol) and EtoAc 1 mL with a 5 mm triple- resonance cryoprobe ('H , 13C, 15N ) with
were used and the product was purified by flash column a z -axis gradient was utilized for all 1D ' H NMR experi
chromatography on silica gel ( step gradient of 20 % to 40 % ments. Acquisition of NMR spectra was automated using a
EtOAc/Hex ) to afford 0.0189 g of the unprotected acid 10 BACS- 120 sample changer and Icon NMR software . All
(90 % ) as low -melting white solid : R -0.3 (6 :4 :0.05 of 55 spectra were acquired at 298.15 K with 16 dummy scans, 64
Hex : EtOAc:AcOH ); m.p. = 35-37 ° C .; IR (ZnSe , cm-?) 3094 scans, 32K data points , a spectral width of 5482.46 Hz, and
(br ), 2923, 2853 , 1780 , 1705 cm- ?; 'H NMR : 8 10.61 (br s , a relaxation delay of 1.5 s. The NMR spectra were processed
1H , COOH ), 3.17-3.08 (m , 2H ), 2.69-2.61 (m , 2H ), 2.35 (br and analyzed using ACD / 1D NMR Manager (Advanced
t, J = 7.6 , 2H ), 2.39-2.31 (br, 1H ), 1.69-1.53 (br m , 4H ), 1.32 Chemistry Development). The resulting 1D 'H NMR spec

(br s, 8H ); 13C NMR : 8 208.8 , 179.9, 52.5 , 36.3 , 34.0, 29.2 , 60 tra were visually inspected for evidence ofmicelle formation

29.1, 28.9 , 28.2 , 24.6 , 23.8; HRCI-MS: calcd . for
C12H2003Na, 213.1491. Found [M +Na]*: 213.1490 . Purity
>97 % by HPLC (retention time, 10.75 min ).

(peak broadening ), or chemical instability / impurities (addi
tional peaks ).
As exemplified in FIG . 2 , the results demonstrate the

3-(Octanoic acid benzyl ester)cyclobutanol (DA6 ) was analogs to be stable in aqueous buffer. The analogs based
prepared similarly to reduction of compound OA6: the 65 upon an octadecanoic acid (1, 2 , 3 , 4 , 5 , 6 , and 7 ) scaffold
mixed cyclobutanone DA5 ( 0.0509 g , 0.17 mmol) in anhy aggregate at concentrations as low as 100 uM . The analogs
drous MeOH (2.5 mL ) and NaBH4 (0.0127 g , 0.34 mmol) based upon a decanoic acid backbone (8 , 9, 10 , and 11) do

US 10,538,475 B2
48

47

not form micelles or other aggregates at concentrations
below 1 mM , the measured MICs (vida infra ).
TABLE 1
critical micellar coefficient (CMC )

of analogs under assay conditions
CMC

21000 UM

s100 UM

Analogs

1, 2 , 3 , 4, 5, 6, 7

8 , 9 , 10 , 11

Indicated concentration or range indicates onset of aggregation observed by 'H NMR of

buffer solutions, see experimental

Example 3 — Measurement of Nonspecific

Cytotoxicity

RAW 264.7 macrophages were incubated with 0-100 UM
of oleic acid or the C18 cyclobutene fatty acid 1, each
delivered as bovine serum albumin complexes. After 24 h ,
cell viability was relative to untreated controls was assessed
using an IN CTYOTOX -CVDE Crystal violet Dye Elution
Kit.

As illustrated in FIG . 4 , the cyclobutene analogue 1
showed little toxicity at 50 uM and only modest toxicity at
100 „ M ; most naturally occurring fatty acids, represented
here by oleate , display some toxicity this cell line at con
centrations 2200 UM (Russell , D. G. et al., Science 2010 ,
328: 852-856 ; and McShane, H., Trans. R. Soc . B 2011, 366 ,
2782-2789 ). The low toxicity against a mammalian cell line
supports
the potential investigations into the modified fatty
acids as potential antimicrobials .
Example 4Bacterial Strains and Culture

verify retrospectively the desired CFU /ml for each strain .
Plates were incubated at 37 ° C. for 3-4 day (M. smeg ) or 5-7
weeks (M. tb ). MIC values were determined by the consis
tent results of three biological and three technical replicates.
5 The MIC was defined by taking themode of three indepen
dent cultures where the MIC did not differ by more than one
doubling dilution , discarding any results that are two dou
bling dilutions away from the mode.
MICs were initially determined against M. Smeg
10
(mc2155 ), a non - pathogenic mycobacteria used as a model
forM.tb to analyze processes that are likely to be conserved
in the genus, and against two M.tb strains (CDC1551 and
H37Rv). DSC , a clinically used TB drug , was employed as
15 a control since MIC determinations for this compound have
been standardized numerous times under different condi
tions in our laboratories. The analogs were added to wells as
solutions in DMSO -do; the deuterated solvent was chosen
for convenience to enable consistency with planned NMR
20 nobasedapparent
metabolomics
. Importantly
, the ,DMSO
-dohad
effect onstudies
the growth
of M. smeg
and contami
nation was not evident in the compound stock control wells
or the media control wells . For M.tb , the combined analysis
of 12 replicates for each of three independent cultures
25 tbindicated
significant
inhibition
either M.in
strain . noResults
for the
fatty acidby DMSO
analogs-d ,areforshown
Table 2 and FIG . 3.M. smeg was in general more resistant
than M. tb to these analogs and DCS. The best MIC values
against M. smeg were observed for 2 , the C18 - cyclobutanone
30 MIC
(3), 8,forandDCS
the C1o
and were
the
(313-cyclobutanol
uM ). Notably11, ,four
of thesimilar
eleven tomol
ecules have MIC values < 100 uM for both M. tb strains :

these include the C18 cyclobutane (2), the C1o cyclobutene

Conditions

35

Bacterial strains used in this study are M.smeg (mc2155 )
and two strains of M. tb (CDC 1551 and H37Rv). Bacterial

(8 ), the C10 cyclobutane (9 ), and the C18 cyclobutanol (4 ).
These MIC values were lower than thatmeasured ( 122 uM )
for the second line antituberculosis drug D -cycloserine
(DCS). Four other analogs yielded lower MICs compared
with DCS in M. tb H37Rv; three others yielded higher MIC

cells were grown with shaking at 37 ° C. in complete
Middlebrook 7H9 broth supplemented with 0.05 % v /v values than DCS.
Tween 80 to an OD600 of 0.6-1.2 . For MIC determinations, 40
TABLE 2
cells were inoculated into a modified previously reported
minimalmedium (Chacon et al 2002 REF ) with components
MIC values against M.smeg and M. tb
and final concentrations as follows: 22 mM dibasic potas

sium phosphate, 16 mM monobasic potassium phosphate,
2.8x10-5 mM ferric chloride, 8.7x10-3 mM zinc sulfate, 45
8.4x10-4 mM cobalt (II) chloride, 1.0x10-2 mM manganese
chloride, 6.8x10-2 mM calcium chloride, 2.4 mM magne
sium sulfate , 5.0 mM ammonium chloride, 25 mM glycerol,

and 0.02 % v /v Tyloxapol. The use of minimal media was

dictated by preliminary experiments indicating that standard 50
complete Middlebrook 7H9 media components may inter
fere with the MIC assay for some of these lipid analog
compounds .

M. smeg ! (mc2155 ) M. tbl (CDC1551). M.tbl (H37Rv)
Tested

MIC3

MIC

molecule ?

(ug/ml)

(UM )

DCS

75
128
64

313
415

64

197
784
713
830
713
752

1
2
3
4
5
6
7

256
256
256
256
128

206

MICH
(ug/ml)

MIC

MIC4 MIC

(UM )

(ug /ml) (UM )

12.5
128
8
64

122
415
26
197

12.5
16
16
32

8

24
713

2
16

415
713

16
256
32

256
128
256
32

122
52
52
99
6
45
52
713

Decanoic
188
188
55 acid (DA)
Example 5 – Druz Susceptibility Assays
8
64
326
4
4.
20
20
4
4
9
128
20
20
645
For MIC testing , each fatty acid analog compound was
603
603
256
10
128
128
1,206
suspended in 100 % DMSO - d , at either 100 mM (M. smeg )
11
302
299
128
597
64
64
or 100 mg/ml (M. smeg and M. tb ) . An equivalent concen
tration DMSO -do was tested separately . The concentration 60 Utilized
3 biological replicates and 3 technical replicates;
All stocks are in 100 % hexadeutero dimethyl sulfoxide (DMSO -d6);
gradients , expressed in ug/ml(compound ) and % DMSO -da, 3The
highest concentration tested was 1024 ug/ml;
were generated using a power- 2 series and varied between
The highest concentration tested was 256 ug/ml
experiments. MICS were determined by a 96 -well
microplate twofold dilution method . Bacteria were har
The MIC results demonstrate promising levels of inhibi
vested , washed 2x with minimalmedia, and inoculated to an 65 tion with a variety of four-membered ring carbocycles
initial concentration of approximately 1.0x105 colony form
(cyclobutanol, cyclobutanone, cyclobutene, and cyclobu
ing units ( CFU ) perwell. The initial inoculum was plated to tane ). The measured MICs vary more than a hundred fold
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against M. tb H37Rv and more than thirty fold against strain
CDC1551; a much smaller range is observed against M.
smeg. Moreover, the nature of the functionality clearly has
an impact on activity. The different influences of function
ality
within the C18 and C10 series are also notable; for 5
example , the short-chain cyclobutanone ( 10 ) and cyclobu
tanol ( 11) are less potent toward mycobacteria than the
corresponding long -chain analogs (3 and 4 ), while the
opposite trend is observed with the cyclobutenes (8 vs. 1 or
6 ) or cyclobutanes (9 vs. 2 or 7) . The cis /trans configuration 10
of the four-membered carbocycle (monochlorocyclobu

tanones 5 vs. 7 ) appears to have a substantial influence on
for cyclobutenes 1 and 6 .
Most of our analogs (8 out of 11 ) show lower MIC values 15

MICs for M. tb . (H37Rv); however , no different is observed

in M. tb than M. smeg . The five to ten fold differences
between MICs for M. smeg and M.tb with some analogs (2 ,
4 , 6 , 8 and 9 )may result from a mechanism of action specific
to M. tb . Isoniazid , for example , demonstrates 100 - fold
more potent inhibition ofM.tb compared with M. smeg and 20
possesses no toxicity toward other mycobacteria and pro
karyotic pathogens. The influence of the analogs may be
specific to a metabolic pathway only found in M. tb such as
at the final elongation step . It is also possible that our
four-membered ring analogs are converted into analogs of 25
mycolic acids and that the physical properties of these
unnatural cell wall constituents results in cell death .

Other Embodiments
30

It is to be understood that while the invention has been

described in conjunction with the detailed description
thereof, the foregoing description is intended to illustrate

and not limit the scope of the invention , which is defined by
the scope of the appended claims. Other aspects, advantages, 35
and modifications are within the scope of the following

claims.

What is claimed is :

1. A compound of Formula (I):

40

R2

R!

45

R3 — Z

R4

or a pharmaceutically acceptable salt thereof,
represents an optionally present double bond ;
R and R2 are independently selected from the group

wherein :

NRCIRPI, NRC(O )R51, NRC(O )ORI, NRC
(O )NRCIR (I, NRCIS(O )RI, NR S(O ),R” 1, NRCIS
(O ),NRCRai, S(O )RbI S(O )NRIRT s 0 )R1,
S (O )2NR IRdl and oxo ;

each Ral, Rb1,R1,Rdl, is independently selected from
C1-4 haloalkyl, C2-6 alkenyl , C2-6 alkynyl, C6-10 aryl ,
C3-10 carbocyclyl, 5-10 membered heteroaryl , 4-10
membered heterocyclyl, C6-10 aryl-C1-4 alkyl, C3-10
carbocyclyl-C1-4 alkyl, (5-10 membered heteroaryl)
C1-4 alkyl or (4-10 membered heterocyclyl) -C1-4
alkyl, wherein said C26 alkenyl, C2-6 alkynyl, C6-10
aryl, C3-10 carbocyclyl, 5-10 membered heteroaryl,

4-10 membered heterocyclyl, C6-10 aryl-C1-4 alkyl,
C3-10 carbocyclyl- C -4 alkyl, (5-10 membered het
eroaryl)-C1-4 alkyl and (4-10 membered heterocy
clyl)-C1-4 alkyl is optionally substituted with 1, 2 , 3 ,
4 , or 5 substituents independently selected from C1-4
alkyl, C1-4 haloalkyl, halo , CN , OR04, SR04, C (O )
Rb4, CONR + Rd4, C ( O )ORC4 , OC (O ) Rb4, OC (O )
NRC4Rd4
NR4Rd4, NRC4C (O )Rb4, NRC4C (O )
NR4R04 NR 4C (O )OR 44 CNR 4 )NR *R44
.

NRCACE= NR24 )NRC4Rd4, S (O )Rb4 , S (O )NR + Rd
S (O )2Rb4 NRCS(O ),Rb4, NRCAS (O )2NR “Rd4 and
S (O ) NR +Rd4
each Ra4, R64, RC4 and Rd4 is independently selected
from H , C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl and
C2-4 alkynyl, wherein said C -4 alkyl, C2-4 alkenyl,
and C2-4 alkynyl, is optionally substituted with 1, 2,

or 3 substituents independently selected from OH ,
CN , amino , halo , C1-4 alkyl, C1-4 alkoxy, C1-4 alky
Ithio , C -4 alkylamino , di( C -4 alkyl)amino , C1-4
haloalkyl, and C -4 haloalkoxy ; and
Z is selected from the group consisting of: COR , COZH ,
NHC (O )NRÖR ?, CONR , OCOR , ORÓ, SR “, NROR ,
and OPO ,Rº,
Ris C - C6 alkyl;
R? and R ’ are independently H or C - C . alkyl; and
wherein the hydrocarbon backbone formed by R4 and
R3 - Z is amphiphilic .
2. The compound of claim 1, wherein R and R² are
independently selected from the group consisting of: H ,
halo , and —O .
3. The compound of claim 1 , wherein the compound is
selected from the group consisting of:

50

consisting of: H , halo , OR®, and = 0 ;
R? is an optionally substituted C3- C40 alkyl;
R * is C2-C30 alkyl optionally substituted with Cy', C1-6 55
alkyl, C2-6 alkenyl, C2-6 alkynyl, halo , C1-6 haloalkyl,
CN , NO2, ORCI , SRAT, C (O )RI, C (O )NRCIRDI, C (O )
ORI, OC (O )NRRdi, Ce= NR )NRCIR'I, NRC

ENRI)NRCRI, NRIRI, NRCÍC (ORI, NRCIC
OOR NRICONRRI, NR ISORI, NRCS 60
(O ) Rb1, NRCIS (O )2NRCIRDI, S (O )RbI, S (O )NRCIRd1
S (O )2Rb1 and S(O )2NRCIR'I;
each Cylis independently C -10 aryl, Cz.10 carbocyclyl,
5-10 membered heteroaryl or 4-10 membered het
erocyclyl, each of which is unsubstituted or substi- 65
tuted by 1, 2, 3 , 4 or 5 substituents independently

selected from Cl-, alkyl, C2-6 alkenyl, C2-6 alkynyl,

halo , CN , NO , ORI, SRal, C (O ) Rbi, c (0 )
NRCRI, C (O ORI, OC (O )RÓI, OC (O )NRCRAI,
CENRel)NRCIRd1, NRC NRENRCRDI,

R4

R3 — Z R4

R4

R3 - Z

CI

R4

R3 — Z R4

0

R3 — Z

R3 — Z

CI

R4

R3 - Z

or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1, wherein R4 is a C2-C10 alkyl .
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5. The compound of claim 1, wherein Z is CO2H .
6. The compound of claim 1, wherein the compound is a
compound of Formula ( II ):
5

R2

R!

poll.

10

R3 - Z

or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1, wherein the compound is a
compound of Formula (III):
R1

CgHìg

( CH2)7CO2H

C8H18

CI

(CH2)7CO2H

or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising a com

pound of Formula (I):
R!

R2

R4

R3—2

15

R2
20

R4

R3 — Z

or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1, wherein the compound is
selected from the group consisting of:

25

( CH2)7CO2H

C8H18

C3H18

S (O ), R51 and S (O ),NR Rdi
each Cyl is independently C6-10 aryl, C3-10 carbocyclyl,

35

(CH2)7CO2H

C8H18

(CH2) 7CO2H
CI
40

(CH2)7CO2H

C8H18

C8H18

45

selected from the group consisting of:

50

CgHj8

(CH2)7CO2H

C3H18

(CH2)7CO2H
55

C3H18

( CH2)7CO2H

CgHj8

(CH2)7CO2H

(CH2)7CO2H

C2H18
CI

(CH2)7CO2H

C2H18

(CH2)7CO2H

60

C8H8

X

O

65

( CH2) 7C02H

5-10 membered heteroaryl or 4-10 membered het

erocyclyl, each of which is unsubstituted or substi
tuted by 1 , 2 , 3 , 4 or 5 substituents independently
selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl ,
halo , CN , NO , ORCI , SRal, C (O )RI, C (O )
NRCRai
, ' C(O Oral, OC (O )Rbi, OC (O )NR Ral
CENREINRIRI, NRCICE NR NR Rd

NRC'RI, NRC C (O )R01, NR C (O )Orál, NRIC

(CH2) 7CO2H

or a pharmaceutically acceptable salt thereof.
9. The compound of claim 8 , wherein the compound is

OR , OC(O )NRCIRdí, CNRI)NRCIRDI, NRCI?
(O )ORI, NRIC (O NRCRAI, NRCIS (O )RÞI, NRCIS

ENRI)NRCRDI, NRCRI, NR - C (ORI, NRC

(O ),R "!, NRCIS (O )2NRCROI, S (O )R1, S(O )NR Irdi

( CH2) 7CO2H

O

C8H18

or a pharmaceutically acceptable salt thereof,
wherein :
represents an optionally present double bond;
R and R2 are independently selected from the group
consisting of: H , halo, OR , and = 0 ;
R is an optionally substituted C3- C40 alkyl;
R * is C -C40 alkyl optionally substituted with Cy ?, C1-6
alkyl, C2-6 alkenyl, C2-6 alkynyl, halo , C1-6 haloalkyl,

CN, NO2, ORCI, SRT, C (O )RI, C (O )NRCIRI, CO )

30

C3H18

XX
-continued

(O )NRCIR'I, NRC?S(O )R " , NRCIS(O ), R " Í, NRCIS
(O ) NRCIR “ , s (o )RÍ, S (O )NRCIRT, s (0 ) R " ,

S (O )2NR Rd and oxo ;
each Ral, RbI, RCI, Rdl, is independently selected from
Chaloalkyl, C2. alkenyl, C2-6 alkynyl, C6-10 aryl,
C3-10 carbocyclyl , 5-10 membered heteroaryl, 4-10
membered heterocyclyl, C6-10 aryl-C1-4 alkyl, C3-10
carbocyclyl-C1-4 alkyl, (5-10 membered heteroaryl)
C1-4 alkyl or (4-10 membered heterocyclyl) -C1-4
alkyl, wherein said C2 6 alkenyl, C2-6 alkynyl, C6-10
aryl, C3-10 carbocyclyl , 5-10 membered heteroaryl,

4-10 membered heterocyclyl, C6-10 aryl- C -4 alkyl,
C3-10 carbocyclyl- C -4 alkyl, (5-10 membered het
eroaryl)-C -4 alkyl and (4-10 membered heterocy
clyl)-C1-4 alkyl is optionally substituted with 1, 2 , 3 ,
4 , or 5 substituents independently selected from C1-4
alkyl, C1-4 haloalkyl, halo , CN , OR04 , SR04, C (O )
Rb4, C (O )NR Rd4, C ( O )ORC4 , OC (O ) Rb4, OC (O )
NRC4Rd4, NR4R04, NRCAC (O )Rb4, NRC4C (O )
NR -Rd4 NRC4C (O )OR44 CNR 4 NRRd4
NRC4CNR 4)NR +Rd4 S (O ) Rb4, S (O )NR + Rdd4
S (O )2Rb4 NRCS(O ) Rb4, NRC4S (O )2NR “Rd4 and
S (O ) NR -Rd4
each Ra4,Rb4,RC4 and Rd4 is independently selected from
H , C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl and C2-4
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alkynyl, wherein said C1-4 alkyl, C2-4 alkenyl, and C2-4

chelonae, Mycobacterium bolletti, Mycobacterium fortui

alkynyl, is optionally substituted with 1 , 2 , or 3 sub tum clade, Mycobacterium parafortuitum clade , Mycobac
stituents independently selected from OH , CN , amino , terium vaccae clade, and CF.
halo , C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio , C1-4 alky
13. The method of claim 11, wherein the mycobacterial
lamino , di( C -4 alkyl)amino, C -4 haloalkyl, and C -4 5 infection is M. tuberculosis.
haloalkoxy ; and
14. The compound of claim 1 , wherein R4 is a C3-C20
Z is selected from the group consisting of: COR ”, CO H ,

CONRÓ, OCOR , ORÓ, SR “, NRÖR ?, and OPOZR ";
R $ is C -Co alkyl;
R and R7 are independently H or C.-C. alkyl; and
wherein the hydrocarbon backbone formed by R4 and
R - Z is amphiphilic
and a pharmaceutically acceptable carrier.

alkyl.

10

11. A method for treating a mycobacterial infection in a
patient, the method comprising administering to the patient 15
a therapeutically effective amount of a compound of For
mula (I):
R!

R2

R4

R3 - Z

20

15. The compound of claim 1 , wherein R4 is a C10 -C30
16. The compound ofclaim 1, wherein R * is a C2- C , alkyl.
17. The compound of claim 1, wherein R4 is a Cg alkyl .

alkyl.

18. A compound selected from the group consisting of:
HO

??

C3H18

C3H18

* (CH2) 7CO2H

(CH2)7CO2H

?? .

(CH2) 7CO2H

(CH2) 7CO2H

(CH2)7CO2H

" ( CH2)7CO2H

25

or a pharmaceutically acceptable salt thereof,
wherein :

represents an optionally present double bond ;

R ! and R² are independently selected from the group 30 ??.
consisting of: H , halo , OR ” , and = 0 ;
R3 is absent or is an optionally substituted C ,-C40 alkyl;
R * is H or an optionally substituted C. - C40 alkyl; and
Z is selected from the group consisting of: COR ”, CO2R “, CH18
CONR , OCOR , OR , SR , NR R ?, and OPOZR ; 35
R is H or C.-C. alkyl;
R? and R ’ are independently H or C.-C. alkyl;

wherein
the backbone formed by R + and R3Zis amphi
philic

OH

(CH2)7C02H

C8H18

(CH2)7CO2H

HO

( CH2) 7CO2H

( CH2) 7CO2H

12. The method of claim 11 , wherein the mycobacterial

infection is a member of a group selected from : Mycobac- 40
terium tuberculosis complex (MTBC ), Mycobacterium

( CH2)7CO2H
(CH2)7CO2H
avium complex (MAC ), Mycobacterium gordonae clade ,
Mycobacterium
kansasii
clade
,
Mycobacterium
nonchro
mogenicum /terrae clade , Mycolactone -producing mycobac
teria , Mycobacterium simiae clade, Mycobacterium che- 45 or a pharmaceutically acceptable salt thereof.
lonae clade, Mycobacterium abscessus, Mycobacterium

